Novel anti-ANG-2 antibodies and their applications
By developing single-domain antibodies and multi-specific fusion proteins that specifically bind to Ang-2, the problem of insufficient binding affinity in existing technologies has been solved, enabling effective prevention and treatment of Ang-2 activation-related diseases.
Patent Information
- Application Number
- CN202580029809.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-02-23
- Filing Date
- 2025-02-24
- Publication Date
- 2026-11-17
AI Technical Summary
There is a lack of anti-Ang-2 antibodies in the current technology that exhibit improved binding affinity and potency to the Ang-2 protein, while also showing excellent therapeutic activity against related diseases.
The development of single-domain antibodies (sdAbs) that specifically bind to Ang-2 or their antigen-binding fragments, including multispecific fusion proteins, polynucleotides encoding antibodies or fusion proteins, expression vectors and host cells, methods for producing antibodies, and pharmaceutical compositions comprising the antibodies for the prevention or treatment of diseases associated with Ang-2 activation or overexpression.
Anti-Ang-2 antibodies have high affinity and specificity, effectively interfering with the binding of Ang-2 to TEK/Tie2, activating the TEK/Tie2 pathway, and without interfering with the activation of Ang-1. They can be used to prevent or treat diseases related to Ang-2 activation.
Smart Images

Figure CN123125232A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to a novel single-domain antibody (sdAb) that specifically binds to Ang-2 or an antigen-binding fragment thereof; a multispecific fusion protein comprising the same; a polynucleotide encoding the antibody or fusion protein; an expression vector comprising the polynucleotide; a host cell comprising the expression vector; a method for producing the antibody, comprising culturing the cell; a pharmaceutical composition for preventing or treating diseases associated with Ang-2 activation or overexpression, comprising the antibody; and a method of using the same for preventing or treating diseases associated with Ang-2 activation or overexpression. Background Technology
[0002] Angiogenesis is the process by which new blood vessels emerge from existing vessels, playing a crucial role in a wide range of physiological and pathological conditions. The formation and maintenance of blood vessels involve numerous anti-angiogenic and pro-angiogenic factors. Representative pro-angiogenic factors include vascular endothelial growth factor (VEGF) A, B, C, and D, basic fibroblast growth factor (bFGF), placental growth factor (PlGF), and angiopoietin (Ang). Anti-angiogenic factors include thromboretin (TSP), angiostatin, endostatin, pigment epithelial-derived factor (PEDF), and soluble decoy receptors composed of the extracellular domains of angiogenic factor receptors. Members of the VEGF family are activated as homodimers or heterodimers. VEGF-A, in particular, exists as six isoforms (VEGF121, VEGF145, VEGF165, VEGF183, VEGF189, and VEGF206) due to alternative splicing during its expression. Members of the VEGF family regulate downstream cell signaling through homodimers or heterodimers of three receptors: vascular endothelial growth factor receptor 1 (VEGFR1, Flt-1), vascular endothelial growth factor receptor 2 (VEGFR2, KDR), and vascular endothelial growth factor receptor 3 (VEGFR3, Flt-4). In addition to the VEGF family, angiogens are involved in angiogenesis during embryonic development and development into adulthood. Representative examples include angiogenin-1 (Ang-1), which acts as an agonist of the TEK receptor tyrosine kinase (TEK / Tie2) pathway, and angiogenin-2 (Ang-2), which functions as either an agonist or antagonist depending on the surrounding cellular environment.
[0003] These various pro-angiogenic factors stimulate peripheral vascular endothelial cells according to their respective functions, bind to multiple receptors, and activate cells through downstream signaling pathways, thereby promoting cell migration and proliferation. Conversely, from the completion of development to adulthood, anti-angiogenic factors inhibit excessive angiogenesis or help immature blood vessels that have already formed acquire normal structure. However, when the balance among these numerous factors with opposing functions is disrupted, vascular diseases may be induced or existing pathological conditions may be exacerbated. Abnormal angiogenesis is known to be a cause of various diseases, including retinal vascular ophthalmological disorders, rheumatoid arthritis, and psoriasis.
[0004] Meanwhile, in diseases associated with abnormal angiogenesis, inactivation of the TEK / Tie2 receptor (a cell membrane tyrosine kinase present on vascular endothelial cells) has been shown to be closely related to the progression of retinal vascular diseases. TEK / Tie2 is a receptor tyrosine kinase present in vascular endothelial cells and perivascular cells; it is mainly expressed in vascular endothelial cells and plays a key role in stabilizing and remodeling new blood vessels (Dumont DJ et al., Oncogene 8:1293-1301, 1993). To date, four ligands of the TEK / Tie2 receptor have been identified: angiopoietin-1 (Ang-1), angiopoietin-2 (Ang-2), angiopoietin-3 (Ang-3), and angiopoietin-4 (Ang-4) (Yancopoulos GD et al., Nature 407:242-248, 2000). Among these, the roles of Ang-1 and Ang-2 have been the most actively studied. Ang-1 acts as a potent agonist of TEK / Tie2 receptor signaling, while Ang-2 functions as an antagonist or partial agonist depending on cell state and the form of cells expressing TEK / Tie2. Elevated vitreous Ang-2 levels have been confirmed in patients with retinal vascular diseases, including wet age-related macular degeneration (wAMD), diabetic macular edema (DME), diabetic retinopathy (DR), and retinal vein occlusion (RVO), compared to normal subjects (EMBO Molecular Medicine 2016;8:1265-1288). Overexpression of Ang-2 leads to pericyte detachment from vascular endothelial cells in retinal vessels, increases endothelial cell sensitivity to VEGF and inflammatory factors, and induces TEK / Tie2 inactivation. Therefore, Ang-2 inhibits TEK / Tie2 signaling, resulting in loss of vascular stability and increased vascular leakage. In contrast, Ang-1 contributes to vascular stability and remodeling by recruiting pericytes, including pericytes, and by activating the TEK / Tie2 pathway to maintain endothelial cell resting.
[0005] Despite the development of various drugs for vascular diseases (Korean Patent No. KR 10-1913940 B1), there is still a need to develop novel anti-Ang-2 antibodies that exhibit improved binding affinity and potency to the Ang-2 protein while demonstrating excellent therapeutic activity against related diseases. Summary of the Invention
[0006] [Technical Issues] The technical problem to be solved by the present invention is to provide a novel single-domain antibody (sdAb) or antigen-binding fragment thereof that specifically binds to angiopoietin-2 (Ang-2); a multispecific fusion protein including the thereof; a polynucleotide encoding the antibody or fusion protein; an expression vector including the polynucleotide; a host cell including the expression vector; a method for producing the antibody, including culturing the cell; a pharmaceutical composition for preventing or treating diseases associated with Ang-2 activation or overexpression, comprising the antibody; and a method of using the thereof for preventing or treating diseases associated with Ang-2 activation or overexpression.
[0007] [Technical Solution] One object of the present invention is to provide a single-domain antibody (sdAb) or an antigen-binding fragment thereof that specifically binds to angiopoietin-2 (Ang-2), wherein the single-domain antibody comprises: (i) a CDR1 comprising an amino acid sequence selected from SEQ ID NO: 11, SEQ ID NO: 14, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 23, SEQ ID NO: 26, SEQ ID NO: 29, SEQ ID NO: 32, SEQ ID NO: 35 or SEQ ID NO: 38; (ii) a CDR2 comprising an amino acid sequence selected from SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 21, SEQ ID NO: 24, SEQ ID NO: 27, SEQ ID NO: 30, SEQ ID NO: 33, SEQ ID NO: 36 or SEQ ID NO: 39; and (iii) a CDR2 comprising an amino acid sequence selected from SEQ ID NO: 13, SEQ ID NO: 16, SEQ ID NO: 38 or SEQ ID NO: 39. CDR3 of the amino acid sequences of NO: 19, SEQ ID NO: 22, SEQ ID NO: 25, SEQ ID NO: 28, SEQ ID NO: 31, SEQ ID NO: 34, SEQ ID NO: 37 or SEQ ID NO: 40.
[0008] Another object of the present invention is to provide a multispecific fusion protein comprising: a single-domain antibody (sdAb) that specifically binds to Ang-2 or an antigen-binding fragment thereof; and a second antigen-binding moiety.
[0009] Another object of the present invention is to provide a bispecific antibody that simultaneously binds Ang-2 and VEGF, comprising: a single-domain antibody (sdAb) that specifically binds Ang-2 or an antigen-binding fragment thereof; and an anti-VEGF antibody that specifically binds VEGF or an antigen-binding fragment thereof.
[0010] Another object of the present invention is to provide a polynucleotide encoding a single-domain antibody (sdAb) that specifically binds to Ang-2, its antigen-binding fragment, or a fusion protein.
[0011] Another object of the present invention is to provide an expression vector comprising the polynucleotide.
[0012] Another object of the present invention is to provide a host cell comprising the expression vector.
[0013] Another object of the present invention is to provide a method for producing antibodies, comprising culturing the host cells.
[0014] Another object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of diseases associated with Ang-2 activation or overexpression, comprising a single-domain antibody, an antigen-binding fragment thereof, or a fusion protein that specifically binds to Ang-2 as an active ingredient.
[0015] Another object of the present invention is to provide a method for preventing or treating diseases associated with Ang-2 activation or overexpression, comprising administering the pharmaceutical composition to a subject.
[0016] [Beneficial Effects] The novel anti-Ang-2 antibody of this invention exhibits high affinity and specificity for Ang-2. Therefore, the antibody of this invention can effectively interfere with the binding of Ang-2 to TEK / Tie2, thereby activating the TEK / Tie2 pathway. Furthermore, the anti-Ang-2 antibody of this invention has high binding affinity for Ang-2, while having no or very low affinity for Ang-1, thus effectively interfering with the function of Ang-2 without interfering with the activation of TEK / Tie2 via Ang-1. Therefore, the anti-Ang-2 antibody of this invention can be effectively used for the prevention, treatment, or diagnosis of diseases associated with Ang-2 activation or overexpression.
[0017] The anti-Ang-2 antibody of the present invention, based on its excellent activity, can be provided as a fusion protein with a portion that binds to another target molecule. For example, it can be provided as a fusion protein with a VEGF-binding portion, thereby exerting a synergistic effect in the treatment of vascular diseases. Attached Figure Description
[0018] Figure 1 The SDS-PAGE results of the purified anti-Ang-2 single-domain antibody are shown.
[0019] Figure 2 The results show the comparison of the specific binding (EC50) of the anti-Ang-2 single-domain antibody (GB1-fused sdAb) to the Ang-1 and Ang-2 antigens by ELISA titration.
[0020] Figure 3 The results show the comparison of the specific binding (EC50) of anti-Ang-2 single-domain antibody (Fc-fused sdAb) to Ang-1 and Ang-2 antigens by ELISA titration.
[0021] Figure 4 The results of the analysis show the inhibitory activity of the anti-Ang-2 single-domain antibody against TEK / Tie2 receptor signaling in HUVEC cells.
[0022] Figure 5 The functional activity of the anti-Ang-2 antibody in inhibiting angiogenesis, as measured in a CNV animal model, is shown. The experimental group of the anti-Ang-2 antibody of this invention is denoted as Anti-Ang2.
[0023] Figure 6 The results show the expression and purification of a multispecific fusion protein including the anti-Ang-2 domain antibody portion.
[0024] Figure 7 The results of expression, purification, and purity (SE-HPLC analysis) of three different forms of multivalent and multispecific fusion proteins, including ALTS54B (which is part of a variety of anti-Ang-2 domain antibodies), are shown.
[0025] Figure 8 The concentrations and SDS-PAGE results of the multispecific fusion protein, including the anti-Ang-2 domain antibody portion, are shown.
[0026] Figure 9 This demonstrates the direct binding (EC50) of a multispecific fusion protein, including the anti-Ang-2 domain antibody portion, to VEGF-A165.
[0027] Figure 10The changes in VEGF-A165 binding absorbance are shown based on the concentration of the multispecific fusion protein, including the anti-Ang-2 domain antibody portion.
[0028] Figure 11 The multispecific fusion protein, including the anti-Ang-2 domain antibody portion, is shown to inhibit the binding of VEGF-A165 to VEGF receptor 1 (VEGFR1) (IC50).
[0029] Figure 12 The absorbance changes show the competitive inhibition of biotinylated VEGF-A165 binding to VEGF receptor 1 (VEGFR1) by a multispecific fusion protein including the anti-Ang-2 domain antibody portion.
[0030] Figure 13 The direct binding (EC50) of a multispecific fusion protein including an anti-Ang-2 domain antibody moiety to Ang-1 and Ang-2 is shown.
[0031] Figure 14 The diagram shows the changes in absorbance at binding to Ang-2 or Ang-1 based on the concentration of a multispecific fusion protein including an anti-Ang-2 domain antibody portion.
[0032] Figure 15 The multispecific fusion protein, including the anti-Ang-2 domain antibody portion, is shown to competitively inhibit the binding of Ang-1 and Ang-2 to the TEK / Tie2 receptor (IC50).
[0033] Figure 16 The absorbance changes are shown to competitively inhibit the binding of biotinylated Ang-2 to the TEK / Tie2 receptor based on the concentration changes of the multispecific fusion protein, which includes the anti-Ang-2 domain antibody portion.
[0034] Figure 17 This study demonstrates the inhibitory activity of a multispecific fusion protein, including an anti-Ang-2 domain antibody portion, on Ang2-induced TEK / Tie2 receptor signaling in HUVEC cells.
[0035] Figure 18 This study demonstrates the inhibitory activity of a multispecific fusion protein, including an anti-Ang-2 domain antibody portion, on Ang2-induced TEK / Tie2 receptor signaling in HUVEC cells.
[0036] Figure 19This demonstrates how a multispecific fusion protein, including an anti-Ang-2 domain antibody portion, restores Akt phosphorylation activity in HUVEC cells by inhibiting Ang-2 and VEGF. V represents VEGF, A1 represents Ang-1, A2 represents Ang-2, and + indicates combined treatment.
[0037] Figure 20 This study demonstrates the inhibitory activity of a multispecific fusion protein, including an anti-Ang-2 domain antibody portion, on VEGF-induced HUVEC cell growth.
[0038] Figure 21 This study demonstrates the inhibitory activity of a multispecific fusion protein, including an anti-Ang-2 domain antibody portion, on HUVEC monolayer permeability induced by VEGF treatment alone.
[0039] Figure 22 This study demonstrates the inhibitory activity of a multispecific fusion protein, including an anti-Ang-2 domain antibody portion, on HUVEC monolayer permeability induced by VEGF treatment alone.
[0040] Figure 23 This study demonstrates the inhibitory activity of a multispecific fusion protein, including an anti-Ang-2 domain antibody portion, on HUVEC monolayer permeability induced by combined treatment with VEGF, Ang-1, and Ang-2.
[0041] Figure 24 This demonstrates the inhibitory activity of a multispecific fusion protein, including the anti-Ang-2 domain antibody portion, on angiogenesis as measured in a CNV animal model. Detailed Implementation
[0042] The present invention will be described in detail below. Furthermore, the various descriptions and embodiments described herein can be applied to other descriptions and embodiments. That is, all combinations of the various elements described herein fall within the scope of the present invention. Moreover, the scope of the present invention is not limited to the specific descriptions below. Additionally, numerous papers and patent documents have been cited throughout this specification. The contents of the cited papers and patent documents are incorporated herein by reference in their entirety to more clearly describe the level of the technical field to which the present invention pertains and the content of the present invention.
[0043] Furthermore, those skilled in the art can identify or characterize numerous equivalents of the specific embodiments of the invention described herein using conventional experiments. Moreover, such equivalents are intended to be included within the scope of this invention.
[0044] Throughout this specification, the standard single-letter and three-letter codes for naturally occurring amino acids are used. Furthermore, the amino acids mentioned herein are abbreviated according to the IUPAC-IUB nomenclature as follows: Alanine (Ala, A) and Arginine (Arg, R) Asparagine Asn, N-aspartic acid Asp, D Cysteine (Cys, C) and Glutamate (Glu, E) Glutamine (Gln, Q) and glycine (Gly, G) Histidine (His, H) and Isoleucine (Ile, I) Leucine (Leu, L), Lysine (Lys, K) Methionine (Met, M) and Phenylalanine (Phe, F) Proline (Pro, P) and Serine (S) Threonine (Thr), T; Tryptophan (Trp), W Tyrosine (Tyr, Y) and Valine (V) Anti-Ang-2 antibody One aspect of the present invention provides an antibody that specifically binds to angiopoietin-2 (Ang-2). The antibody that specifically binds to angiopoietin-2 (Ang-2) in this invention may be referred to hereinafter as an "anti-Ang-2 antibody".
[0045] Specifically, the anti-Ang-2 antibody of the present invention may be a single-domain antibody (sdAb) that specifically binds to Ang-2 or its antigen-binding fragment. In this specification, the single-domain antibody that specifically binds to Ang-2 may also be referred to as "anti-Ang-2sdAb" or "anti-Ang-2 single-domain antibody".
[0046] As used herein, the term "antibody" refers to a protein molecule that acts as a receptor for specifically recognizing an antigen, including immunoglobulin molecules having an immunoreactivity with a specific antigen, and includes polyclonal antibodies, monoclonal antibodies, intact antibodies, and antibody fragments. For the purposes of this invention, an antibody may be an antibody that specifically binds to the Ang-2 protein. Furthermore, the term includes chimeric antibodies, humanized antibodies, human antibodies, and bivalent or bispecific molecules (e.g., bispecific antibodies), biantibodies, triantibodies, and tetraantibodies. The term further includes single-chain antibodies with FcRn binding capability, scaffolds, derivatives of antibody constant regions, and artificial antibodies based on protein scaffolds. An intact antibody has a structure consisting of two full-length light chains and two full-length heavy chains, wherein each light chain is linked to the heavy chain by a disulfide bond. Intact antibodies include IgA, IgD, IgE, IgM, and IgG, and IgG includes subtypes IgG1, IgG2, IgG3, and IgG4. An antibody fragment refers to a fragment with antigen-binding function and includes Fd, Fab, Fab', F(ab')2, Fv, etc. Fd refers to the heavy chain portion included in the Fab fragment. Fab has a structure with variable regions of both the light and heavy chains, a constant region of the light chain, and a first constant region of the heavy chain (CH1 domain), and an antigen-binding site. Fab' differs from Fab in that it has a hinge region at the C-terminus of the heavy chain CH1 domain, comprising one or more cysteine residues. When the cysteine residues in the hinge region of Fab' form disulfide bonds, the F(ab')2 antibody is formed. Fv (variable fragment) refers to the smallest antibody fragment containing only the heavy chain and light chain variable regions. Disulfide-stabilized Fv (dsFv) has heavy chain and light chain variable regions linked by disulfide bonds. Single-chain Fv (scFv) typically has heavy chain and light chain variable regions covalently linked by peptide linkers. These antibody fragments can be obtained using proteases (e.g., Fab can be obtained by limited cleavage of an intact antibody with papain, and the F(ab')2 fragment can be obtained by cleavage of the same antibody with pepsin), and specifically, they can be generated using genetic recombination techniques. Specifically, antibodies can be single-domain antibodies, such as heavy-chain-only antibodies.
[0047] As used herein, the term "single-domain antibody (sdAb)" refers to a single antigen-binding polypeptide having three complementarity-determining regions (CDRs). sdAb refers to the human heavy chain variable domain (V) that provides specific binding affinity within the intact antibody. H ) or human light chain variable structural domain (V L The smallest unit, and includes only single-chain antibodies (V) from sharks, llamas, camels, alpacas, etc. HThe variable domain of H). For the purposes of this invention, a single-domain antibody may refer to a single-domain antibody (sdAb) that specifically binds to Ang-2 and has an epitope that serves as a protein determinant site of the Ang-2 protein.
[0048] The "variable region" or "variable domain" of an antibody refers to the amino-terminal domain of the antibody's heavy or light chain. The variable domains of the heavy and light chains can be respectively referred to as "V..." H " and "V L These domains are typically the most variable parts of an antibody (compared to other antibodies in the same class) and contain antigen-binding sites. For example, V H The structure from the N-terminus to the C-terminus is as follows: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, where FR1 to FR4 each refer to frame regions 1 to 4, and CDR1 to CDR3 refer to complementarity-determining regions 1 to 3.
[0049] "Isolated" antibodies are identified, isolated, and / or recovered from components in the production environment (e.g., natural or recombinant). Preferably, the isolated peptide is not associated with any other components from its production environment. Contaminant components in the production environment, such as those from recombinant transfected cells, are substances that typically interfere with the research, diagnostic, or therapeutic use of the antibody and may include enzymes, hormones, and other protein or non-protein solutes. In preferred specific embodiments, the peptide will be (1) purified to the extent that it is determined by, for example, the Lowry method to be greater than 95% by weight, and in some specific embodiments greater than 99% by weight, of antibody; (2) purified to the extent that at least 15 residues of the N-terminal or internal amino acid sequence can be obtained by using a rotary cup sequencer; or (3) purified to homogenization by SDS-PAGE under non-reducing or reducing conditions using Coomassie blue or preferably silver staining. The isolated antibody includes antibodies in situ within recombinant cells, since at least one component in the native environment of the antibody will not be present. However, typically, the isolated peptide or antibody will be produced by using at least one purification step.
[0050] As used herein, the term "angiopoietin-2 (Ang-2)" includes variants and isotypes of Ang-2 naturally expressed by the ANGPT2 gene. Angiopoietin-2 loosens intercellular connections or induces apoptosis, leading to vascular degeneration. Under normal and abnormal conditions, angiopoietin-2 activates or inhibits the TEK / Tie2 pathway depending on the distribution environment of surrounding angiogenesis regulators. In other words, depending on the environment, Ang-2 acts as an antagonist or partial agonist of the TEK / Tie2 receptor on the cell surface, interacting with other angiogenesis factors, including VEGF, to maintain angiogenesis-related homeostasis under normal conditions. Specifically, Ang-2 competitively binds to the TEK / Tie2 receptor against Ang-1. Under normal conditions, which maintain homeostasis regarding angiogenesis and inhibition, the expression levels of Ang-1 and Ang-2 are in equilibrium; however, in angiogenesis-related diseases, including cancer, diabetic retinopathy, and age-related macular degeneration, there is an imbalance with relatively high Ang-2 levels.
[0051] Therefore, antibodies that specifically recognize Ang-2 can be used to diagnose, prevent, or treat diseases associated with Ang-2 activation or overexpression, and the inventors have developed antibodies that bind to the Ang-2 protein with high affinity. The anti-Ang-2sdAb of the present invention binds to Ang-2 antibodies with high affinity but is not reactive to Ang-1, and is therefore advantageously applicable in the treatment of related diseases.
[0052] The Ang-2 protein of the present invention can be obtained by recombinant methods or purchased from conventional commercial sources. The Ang-2 of the present invention can be in the form of an isolated protein or in combination with another protein or polysaccharide, and specifically in combination with a bacterial exotoxin, but is not limited thereto. In one embodiment, Ang-2 can be human Ang-2, and in one example, the Ang-2 protein can include the amino acid sequence represented by SEQ ID NO: 42.
[0053] The anti-Ang-2 sdAb of the present invention may include: (i) a CDR1 comprising an amino acid sequence selected from SEQ ID NO: 11, SEQ ID NO: 14, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 23, SEQ ID NO: 26, SEQ ID NO: 29, SEQ ID NO: 32, SEQ ID NO: 35 or SEQ ID NO: 38; (ii) CDR2 comprising an amino acid sequence selected from SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 21, SEQ ID NO: 24, SEQ ID NO: 27, SEQ ID NO: 30, SEQ ID NO: 33, SEQ ID NO: 36 or SEQ ID NO: 39; and (iii) CDR3 comprising an amino acid sequence selected from SEQ ID NO: 13, SEQ ID NO: 16, SEQ ID NO: 19, SEQ ID NO: 22, SEQ ID NO: 25, SEQ ID NO: 28, SEQ ID NO: 31, SEQ ID NO: 34, SEQ ID NO: 37 or SEQ ID NO: 40.
[0054] In one embodiment, the anti-Ang-2 sdAb of the present invention may include: (a) CDR1 of SEQ ID NO: 11, CDR2 of SEQ ID NO: 12, and CDR3 of SEQ ID NO: 13; (b) CDR1 of SEQ ID NO: 14, CDR2 of SEQ ID NO: 15, and CDR3 of SEQ ID NO: 16; (c) CDR1 of SEQ ID NO: 17, CDR2 of SEQ ID NO: 18, and CDR3 of SEQ ID NO: 19; (d) CDR1 of SEQ ID NO: 20, CDR2 of SEQ ID NO: 21, and CDR3 of SEQ ID NO: 22; (e) CDR1 of SEQ ID NO: 23, CDR2 of SEQ ID NO: 24, and CDR3 of SEQ ID NO: 25; (f) CDR1 of SEQ ID NO: 26, CDR2 of SEQ ID NO: 27, and CDR3 of SEQ ID NO: 28; (g) SEQ ID NO: (h) CDR1 of SEQ ID NO: 39, CDR2 of SEQ ID NO: 30, and CDR3 of SEQ ID NO: 31; (i) CDR1 of SEQ ID NO: 32, CDR2 of SEQ ID NO: 33, and CDR3 of SEQ ID NO: 34; (ii) CDR1 of SEQ ID NO: 35, CDR2 of SEQ ID NO: 36, and CDR3 of SEQ ID NO: 37; or (j) CDR1 of SEQ ID NO: 38, CDR2 of SEQ ID NO: 39, and CDR3 of SEQ ID NO: 40.
[0055] In one example, the anti-Ang-2 sdAb of the present invention may include CDR1 of SEQ ID NO: 17, CDR2 of SEQ ID NO: 18, and CDR3 of SEQ ID NO: 19; or CDR1 of SEQ ID NO: 29, CDR2 of SEQ ID NO: 30, and CDR3 of SEQ ID NO: 31.
[0056] In one embodiment of the invention, clones exhibiting high reactivity to Ang-2 and low reactivity to Ang-1 were screened, thereby deriving 10 novel antibodies with highly selective antigen-binding activity against Ang-2 and their respective CDRs. This indicates that the anti-Ang-2 sdAb of the present invention can be advantageously used in fields requiring the recognition of Ang-2 protein, such as for the diagnosis or treatment of diseases with Ang-2 protein overexpression.
[0057] In one embodiment, the anti-Ang-2 sdAb of the present invention may include a sequence having 80% or more, 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more sequence identity with the CDR sequence.
[0058] In one example, since the CDR sequence may include mutations made to exclude N-glycosylation sites, the sequence prior to the mutation to exclude N-glycosylation may also be included as a bioequivalence within the scope of this invention.
[0059] In another embodiment, the anti-Ang-2 sdAb of the present invention includes a heavy chain variable region, and the heavy chain variable region may include any amino acid sequence selected from SEQ ID NO: 1 to 10, or a sequence having 80% or more, 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more sequence identity with any amino acid sequence selected from SEQ ID NO: 1 to 10.
[0060] In one example, the anti-Ang-2 sdAb of the present invention includes a heavy chain variable region, and the heavy chain variable region may include the amino acid sequence of SEQ ID NO: 3 or SEQ ID NO: 7, or a sequence having 80% or more, 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more sequence identity with the amino acid sequence of SEQ ID NO: 3 or SEQ ID NO: 7.
[0061] In one specific embodiment, an amino acid sequence variant of the anti-Ang-2 sdAb of the present invention is considered. For example, it may improve the binding affinity and / or other biological properties of the antibody. The amino acid sequence variant of the antibody can be generated by introducing appropriate modifications into the nucleotide sequence encoding the molecule or by peptide synthesis. Such modifications include, for example, deleting residues from the amino acid sequence of the antibody, and / or inserting residues into such amino acid sequences, and / or substituting residues within such amino acid sequences. Any combination of various changes, including deletions, insertions, and substitutions, can be performed to obtain the final composition, but the final composition must have the desired properties, such as antigen-binding properties. Target sites for inducing substitution mutations may include heavy chain variable regions and framework regions.
[0062] In one embodiment, variants may include bioequivalents of the anti-Ang-2sdAb of the present invention within the scope of retaining the antigen-binding characteristics. For example, arginine, lysine, and histidine are positively charged residues; aspartic acid and glutamic acid are negatively charged residues; serine, threonine, asparagine, and glutamine are polar, uncharged residues; alanine, valine, isoleucine, leucine, and methionine are hydrophobic residues; and phenylalanine, tyrosine, and tryptophan are hydrophobic residues with aromatic ring structures. Therefore, when variations are included based on such relative similarities of amino acid residues, they can be considered biologically equivalent.
[0063] In one embodiment, the bioequivalent may include conserved substitutions. As used herein, the term “conserved substitution” is defined as follows, and candidates for conservedly substituted amino acids are indicated in parentheses: Ala (Gly, Ser); Arg (Gly, Gln); Asn (Gln; His); Asp (Glu); Cys (Ser); Gln (Asn, Lys); Glu (Asp); Gly (Ala, Pro); His (Asn; Gln); Ile (Leu; Val); Leu (Ile; Val); Lys (Arg; Gln); Met (Leu, Ile); Phe (Met, Leu, Tyr); Ser (Thr; Gly); Thr (Ser; Val); Trp (Tyr); Tyr (Trp; Phe); and Val (Ile; Leu).
[0064] In one embodiment, the anti-Ang-2 antibody of the present invention can be provided as a multivalent compound linked with two or more anti-Ang-2 sdAbs. Specifically, the anti-Ang-2 antibody of the present invention can be provided as a monovalent sdAb, or in a divalent to tetravalent or higher multivalent form, thereby allowing for increased binding affinity and activity to the target molecule. In particular, the sdAbs can bind directly to each other or be linked via a linker.
[0065] In this invention, the linker can be a non-peptide linker or a peptide linker, without limitation. More specifically, the peptide linker may comprise one or more amino acids, for example, 1 to 1,000 amino acids, and may include any peptide linker known in the art, such as the [GS]x linker, the [GGGS]x linker, the [GGGGS]x linker, etc., where x may be a natural number greater than or equal to 1 (e.g., 1, 2, 3, 4, 5 or more), but is not limited thereto. In one example, the linker may be a peptide linker comprising a sequence of 7 to 20 amino acids, and in a more specific example, the [GGGGS]3 linker of SEQ ID NO: 67 or the GGGGSGGGS linker of SEQ ID NO: 68 may be used, but is not limited thereto.
[0066] The anti-Ang-2 sdAb of the present invention has the property of binding Ang-2 with high affinity.
[0067] In one embodiment, the anti-Ang-2 sdAb can specifically bind to the fibrinogen-like domain (FLD) of the Ang-2 protein. The FLD of Ang-2 can be the fibrinogen-like domain of the human Ang-2 protein. In one example, the fibrinogen-like domain of Ang-2 can include the amino acid sequence represented by SEQ ID NO: 43.
[0068] In one embodiment of the present invention, it was confirmed that the anti-Ang-2 sdAb of the present invention has high affinity and specificity for Ang-2, thereby preventing Ang-2 from binding to the TEG / Tie2 receptor and effectively inducing the activation of the TEK / Tie2 pathway.
[0069] In one example, based on the half-maximum reaction concentration (EC50), the binding affinity of the anti-Ang-2 antibody of the present invention to the Ang-2 antigen can be 10. -6 M to 10 -12 M, and more specifically, the EC50 of the Ang-2 antibody can be 10. -7 M to 10 -12 M, 10 -8 M to 10 -12 M, 10 -9 M to 10 -12 M, 10 -10 M to 10 -12 M, 10 -6 M to 10 -11 M, 10 -7 M to 10 -11 M, 10 -8 M to 10 -11 M, 10 -9 M to 10 -11 M, 10 -10 M to 10 -11 M, 10 -6 M to 10 -10 M, 10 -7 M to 10 -10 M, 10 -8 M to 10 -10 M or 10 -9 M to 10 -10 M. In particular, EC50 can be measured by antibody-antigen ELISA titration.
[0070] The anti-Ang-2 sdAb of the present invention is a single-domain antibody that does not bind to angiopoietin-1 (Ang-1) or has low reactivity to it.
[0071] In one embodiment of the invention, a comparison of the competitive inhibition of binding to the TEK / Tie2 receptor between Ang-1 and Ang-2 confirmed that, based on EC50, the half-maximum concentration (WMC) of the anti-Ang-2 sdAb binding to Ang-2 was more than 1000 times lower than that binding to Ang-1 (Examples 2 and 3), thus confirming that the antibody of the present invention can effectively inhibit the action of Ang-2 without interfering with the activation of TEK / Tie2 by Ang-1. In one example, Ang-1 may include the amino acid sequence represented by SEQ ID NO: 44, and the FLD of Ang-1 may include the amino acid sequence represented by SEQ ID NO: 45.
[0072] The anti-Ang-2 sdAb of the present invention activates the TEK / Tie2 pathway by inhibiting the binding of Ang-2 to the TEK / Tie2 receptor. The TEK / Tie2 pathway is known to play a role in stabilizing vascular structures during angiogenesis. In one embodiment of the present invention, the anti-Ang-2 sdAb of the present invention was confirmed to effectively inhibit the binding of Ang-2 to the TEK / Tie2 receptor (Example 3), and as a result, it was confirmed to exhibit high TEK / Tie2 receptor signaling inhibitory activity (Example 4).
[0073] In one embodiment, the anti-Ang-2 antibody of the present invention may be in the form of fusion with a biocompatible material or carrier that can increase its stability or duration of activity. Specifically, the anti-Ang-2 antibody of the present invention may be in the form of being linked to a biocompatible material or carrier via a linker or covalent bond.
[0074] As used herein, the terms "biocompatible material" and "carrier" refer to substances that, when directly or indirectly linked to the anti-Ang-2 antibody of the present invention via covalent or non-covalent bonds to form a conjugate, can increase the stability or duration of activity of the corresponding anti-Ang-2 antibody. The types of biocompatible materials or carriers that can be used in the present invention are diverse and may be selected, for example, from polyethylene glycol, fatty acids, cholesterol, albumin and fragments thereof, albumin-binding substances, polymers of specific amino acid sequence repeating units, FcRn-binding substances, in vivo connective tissue or derivatives thereof, nucleotides, fibronectin, transferrin, carbohydrates, polymers, and combinations thereof. These biocompatible materials or carriers include biocompatible materials whose in vivo half-life is extended via covalent or non-covalent bonds.
[0075] In one embodiment, the biocompatible material may be the immunoglobulin Fc region or the GB1 domain.
[0076] Specifically, the immunoglobulin Fc region may be selected from: (a) the CH1, CH2, CH3, and CH4 domains; (b) the CH1 and CH2 domains; (c) the CH1 and CH3 domains; (d) the CH2 and CH3 domains; (e) a combination of one or more of the CH1, CH2, CH3, and CH4 domains with an immunoglobulin hinge region or a portion thereof; and (f) a dimer of the domains of the heavy chain constant region and the light chain constant region. In this invention, the immunoglobulin Fc region may also be interchangeably referred to as "Fc," "Fc region," and "Fc site."
[0077] In one example, the immunoglobulin Fc region is characterized by having at least one amino acid in the native immunoglobulin Fc region modified by substitution, addition, deletion, modification, or combinations thereof.
[0078] In one example, the immunoglobulin Fc region may have: a site capable of forming a disulfide bond removed; some amino acids at the N-terminus of the native Fc removed; a methionine residue added to the N-terminus of the native Fc; a complement binding site removed; or an antibody-dependent cell-mediated cytotoxicity (ADCC) site removed.
[0079] In one example, the Fc region of an immunoglobulin can be non-glycosylated.
[0080] In one example, the immunoglobulin Fc region may be derived from IgG, IgA, IgD, IgE, or IgM. In another example, the immunoglobulin Fc region may be the rabbit immunoglobulin IgG region or the human immunoglobulin IgG region.
[0081] In one example, the immunoglobulin Fc region can be a hybrid of domains from different sources, wherein the domains are derived from immunoglobulins selected from IgG, IgA, IgD, IgE, and IgM.
[0082] In another example, immunoglobulin Fc may include, but is not limited to, the amino acid sequence of SEQ ID NO: 47 or SEQ ID NO: 69, or a sequence having 90% or more sequence identity with the amino acid sequence of SEQ ID NO: 47 or SEQ ID NO: 69.
[0083] Specifically, the GB1 domain refers to the B1 domain of the immunoglobulin-binding protein "protein G". In this invention, the GB1 domain can be interchangeably referred to as "GB1" or "protein GB1 domain", etc.
[0084] In one example, the GB1 domain could be the streptococcal protein G B1 domain of protein G derived from Streptococcus, or it could be the GB1 domain of protein G derived from another organism or microorganism.
[0085] In one example, the GB1 domain is characterized by having at least one amino acid in the native GB1 domain modified by substitution, addition, deletion, modification, or combinations thereof.
[0086] In another example, the GB1 domain may include, but is not limited to, the amino acid sequence of SEQ ID NO: 46, or a sequence having 90% or more sequence identity with the amino acid sequence of SEQ ID NO: 46.
[0087] Multispecific fusion protein Another aspect of the present invention provides a multispecific fusion protein comprising: a single-domain antibody (sdAb) that specifically binds to Ang-2 or an antigen-binding fragment thereof; and a second antigen-binding portion.
[0088] The definitions of “angiopoietin-2”, “antibody”, “sdAb” and “single-domain antibody that specifically binds to angiopoietin-2” are as described above.
[0089] As used herein, the term "multispecific fusion protein" refers to a binding molecule possessing two or more binding specificities. The term "multispecific" specifically includes "bispecific" and "trispecific," as well as higher-order specific binding affinities. The term "multispecific fusion protein" is used in its broadest sense herein, including "multispecific antibody," "multispecific heavy chain-only antibody," "multispecific heavy chain antibody," and "multispecific UniAb." TM "and multispecific binding compounds", and includes all binding molecules having more than one binding specificity.
[0090] The anti-Ang-2 antibody of the present invention, based on high Ang-2 specificity, can be fused with other therapeutic proteins, angiogenesis inhibitors, antibodies, etc., to reduce mutual resistance, thereby exerting a synergistic effect and enhancing efficacy in the treatment of vascular-related diseases. In this regard, the anti-Ang-2 antibody of the present invention can be provided in the form of a fusion protein combined with various substances.
[0091] As used herein, the term "second antigen-binding moiety" can include any substance that specifically binds to a target molecule other than Ang-2 (i.e., the second antigen), without limitation, and examples include antibodies, antigen-binding fragments, peptides, aptamers, compounds, non-antibody protein scaffolds, recombinant proteins, or nucleic acids. As a more specific example, it can be a receptor or antibody that binds to factors associated with vascular or inflammatory regulation other than Ang-2. The second antigen-binding moiety can include any substance that can be combined with the anti-Ang-2 antibody of the present invention to enhance efficacy, without limitation.
[0092] The multispecific fusion protein of the present invention may include, in addition to the second antigen-binding portion, a third antigen-binding portion, a fourth antigen-binding portion, ... and an nth antigen-binding portion, without limitation. In particular, n is an integer of 3 or greater. As a non-limiting example, the above-mentioned nth antigen-binding portion may be an antibody, an antigen-binding fragment, a peptide, an aptamer, a compound, a non-antibody protein construct, a recombinant protein, a nucleic acid, etc.
[0093] As an example, the multispecific fusion protein of the present invention can regulate one or more pathways, or regulate two or more pathways selected from the VEGF receptor 1 pathway, VEGF receptor 2 pathway, VEGF receptor 3 pathway, VEGF receptor 4 pathway, Tie1 or TEK / Tie2 receptor pathway, Wnt / β-linkin axis pathway, Norrin pathway, complement system pathway, integrin pathway, VE-PTP pathway, Notch1, 2, 3, 4 / DLL1, 3, 4 axis pathway and tumor necrosis factor (TNF-α) receptor pathway in multiple ways.
[0094] In one example, the second antigen-binding portion could be an anti-VEGF antibody or a soluble VEGF receptor.
[0095] The multispecific fusion protein of the present invention may include a single-domain antibody (sdAb) that specifically binds to Ang-2 or an antigen-binding fragment thereof; and a second antigen-binding portion that can be directly bound or linked via a linker, or may additionally include other protein portions, but is not limited thereto. In particular, "linker" is as defined above. The linking methods and linking sites of the multispecific fusion protein of the present invention are not limited to those methods and sites performed in industry, as long as they do not alter the structure or activity of the protein to be linked.
[0096] In one embodiment, the second antigen-binding portion may be, for example, an antibody. In particular, if the second antigen-binding portion in this invention is an antibody, it may be referred to as a "second antibody".
[0097] In one embodiment, the multispecific fusion protein of the present invention may include an anti-Ang-2 antibody or an antigen-binding fragment thereof, and a second antibody or an antigen-binding fragment thereof.
[0098] As used herein, the term "second antibody" refers to an antibody that has a different target molecule than the anti-Ang-2 antibody and specifically binds to target molecules other than Ang-2. There are no limitations on the second antibody, as long as it is specific to a target molecule different from the anti-Ang-2 sdAb of this invention and can have a synergistic effect or provide additional activity.
[0099] Furthermore, if the multispecific fusion protein of the present invention is a trispecific or higher-specificity nth-specific antibody, the multispecific fusion protein may be supplemented with a second antibody, a third antibody, ... and an nth antibody, each having a target molecule different from Ang-2. In particular, n is an integer of 3 or greater.
[0100] In one embodiment, the anti-Ang-2 antibody and the second antibody may be provided independently in a monovalent form, or in a bivalent to tetravalent or higher multivalent form, wherein the molecules may be provided in a form in which they bind directly to each other or are linked by a linker.
[0101] In one embodiment, the multispecific fusion protein of the present invention may have an anti-Ang-2 antibody and a second antibody sequentially linked from the N-terminus, or may have a second antibody and an anti-Ang-2 antibody sequentially linked from the N-terminus.
[0102] In one embodiment, the anti-Ang-2 antibody and the second antibody may each be independently fused with the aforementioned biocompatible material or carrier, and for example, the biocompatible material or carrier may be the immunoglobulin Fc region or GB1 domain.
[0103] In one example, the multispecific fusion protein of the present invention may be a fusion protein in which an anti-Ang-2 antibody, a biocompatible material or carrier, and a second antibody are sequentially linked from the N-terminus. In another example, the multispecific antibody of the present invention may be a fusion protein in which a second antibody, a biocompatible material or carrier, and an anti-Ang-2 antibody are sequentially linked from the N-terminus. Independently, the second antibody and the biocompatible material or carrier may bind directly to each other or be linked through a adapter, and the biocompatible material or carrier and the anti-Ang-2 antibody may bind directly to each other or be linked through a adapter.
[0104] In one embodiment, the second antibody is not limited, as long as it targets a molecule different from Ang-2, and can be, for example, anti-VEGF antibody, anti-C3b antibody, anti-C5 antibody, anti-ACC2 antibody, anti-RAMP2 antibody, anti-Tie2 antibody, anti-EGFR antibody, anti-αvβ5 antibody, anti-RANKL antibody, anti-influenza antibody, anti-malarial antibody, anti-HCV antibody, anti-HIV antibody, anti-HBV antibody, anti-CK-MB antibody, anti-troponin I antibody, anti-myoglobin antibody, anti-PSA antibody, anti-AFP antibody, anti-CEA antibody, anti-TSH antibody, anti-CSH antibody, anti-hcG antibody, anti-cortisol antibody, anti-progesterone antibody, anti-testosterone antibody, anti-GAD antibody, anti-insulin antibody, anti-IGF antibody, anti-B cell antibody, anti-BlyS antibody, etc.
[0105] In one embodiment, the second antibody may be an anti-VEGF antibody that specifically binds VEGF. In particular, the multispecific fusion protein of the present invention may be a bispecific antibody that simultaneously binds Ang-2 and VEGF, comprising: a single-domain antibody (sdAb) that specifically binds Ang-2 or its antigen-binding fragment; and an anti-VEGF antibody that specifically binds VEGF or its antigen-binding fragment.
[0106] As used herein, the term "vascular endothelial growth factor" or "VEGF" refers to a type of signaling protein that plays an important role in angiogenesis and vascular development. Members of the VEGF family are activated as homodimers or heterodimers. Among the members, VEGF-A exists in six isoforms during its expression due to alternative splicing: VEGF121, VEGF145, VEGF165, VEGF183, VEGF189, and VEGF206. Members of the VEGF family regulate downstream cellular signaling through homodimers or heterodimers of three receptors: vascular endothelial growth factor receptor 1 (VEGFR1, Flt-1), vascular endothelial growth factor receptor 2 (VEGFR2, KDR), and vascular endothelial growth factor receptor 3 (VEGFR3, Flt-4). When blood circulation is insufficient, VEGF functions as part of a system for storing and supplying oxygen to tissues. The general function of VEGF is to promote the formation of new blood vessels in processes such as embryonic development, muscle injury or exercise, and the formation of vessels that bypass infarcted blood vessels. However, increased levels of VEGF can lead to abnormal angiogenesis.
[0107] In this invention, as long as VEGF exhibits effects such as promoting the regeneration of damaged skin, hair regeneration, and growth by inducing angiogenesis, epidermal cell proliferation, promoting cell migration, and increasing microvascular permeability, its amino acid sequence is not particularly limited. The entire amino acid sequence of VEGF, its modified amino acid sequence, or a partial fragment thereof can be used. Specific amino acid sequences of VEGF or nucleotide sequence information of the genes encoding them can be obtained from known databases (e.g., NCBI's GenBank).
[0108] One of the most important angiogenic factors in retinal vascular diseases is VEGF, and anti-VEGF therapy (a strategy that blocks the function of this factor) has been established as the most effective treatment to date. However, such mono-factor inhibitory therapies cannot address choroidal ischemia caused by excessive angiogenesis inhibition and may even cause side effects that worsen symptoms. Therefore, anti-VEGF therapy alone may raise serious concerns about side effects in older or diabetic patients who require angiogenesis in ischemic brain, heart, and extremities. Furthermore, the percentage of patients who do not respond to anti-VEGF therapy in wAMD reaches 30%, and in the case of diabetic macular edema (DME) it reaches 50%, indicating significant room for improvement. In addition, anti-VEGF therapy alone still has considerable room for improvement in drug response rates associated with visual improvement and dryness relief, as well as in the durability of treatment effects associated with intravitreal (IVT) injection intervals, thus constituting a treatment approach with a high degree of unmet medical need.
[0109] According to one embodiment of the present invention, a multispecific fusion protein combining Ang-2 and VEGF solves the problems of conventional anti-VEGF therapy, and can induce angiogenesis stabilization and remodeling through regulation of the TEK / Tie2 pathway, while inhibiting angiogenesis proliferation through regulation of the VEGF pathway. Therefore, the bispecific antibody combining Ang-2 and VEGF of the present invention can simultaneously regulate the VEGF pathway and the TEK / Tie2 pathway, thereby exhibiting a synergistic effect in inhibiting angiogenesis.
[0110] In one embodiment, the inventors generated a fusion protein by combining an anti-Ang-2 antibody and an anti-VEGF antibody, and verified that the fusion protein of the present invention effectively neutralizes Ang-2 to inhibit phosphorylation signaling in the TEK / Tie2 pathway, while possessing high binding properties to VEGF, thereby exhibiting HUVEC growth inhibitory activity. Furthermore, they confirmed significant angiogenesis inhibitory activity in a mouse choroidal angiogenesis animal model. In other words, they confirmed that when the activity of the existing anti-Ang-2 antibody is maintained or enhanced, the inherent activity of the bound second antigen-binding moiety (i.e., the anti-VEGF antibody) is also preserved, ultimately exhibiting a synergistic effect on angiogenesis.
[0111] In one example, the anti-VEGF antibody may be aflibercept, bevacizumab, brolucizumab, conbercept, or ranibizumab, but is not limited to these, as long as it is a VEGF-specific antibody. In a more specific example, the anti-VEGF antibody may be aflibercept, and aflibercept may consist of a VEGFR1 domain, a VEGFR2 domain, and IgG Fc.
[0112] In one example, the multispecific fusion protein of the present invention may be in the form in which an anti-Ang-2 antibody is linked to the N-terminus or C-terminus of aflibercept. In particular, the anti-Ang-2 antibody may comprise a tetravalent or bivalent anti-Ang-2 sdAb. For example, when the anti-Ang-2 antibody comprises a tetravalent anti-Ang-2 sdAb, two sdAbs may be tandemly fused to one of the two heavy chains of the aflibercept IgG1 Fc domain linked by disulfide bonds, and the remaining two sdAbs may be tandemly fused to the other heavy chain of the two IgG1 Fc domain heavy chains. For example, when the anti-Ang-2 antibody comprises a bivalent anti-Ang-2 sdAb, one sdAb may be fused to one of the two heavy chains of the aflibercept IgG1 Fc domain linked by disulfide bonds, and the other sdAb may be fused to the other heavy chain of the two IgG1 Fc domain heavy chains. A schematic structural diagram of the multispecific fusion protein of the present invention according to one embodiment is shown below. Figure 6 and Figure 7 middle.
[0113] In one embodiment of the invention, the multispecific fusion protein of the present invention was confirmed to exhibit excellent activity in various forms, and its expression and production were also highly efficient. This indicates that the high thermostability and protein folding stability of the antibodies of the present invention facilitate the construction of various forms of fusion proteins.
[0114] In one example, the multispecific fusion protein of the present invention may include any sequence selected from SEQ ID NO: 48 to 65, or a sequence having 80% or more, 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more homology with any sequence selected from SEQ ID NO: 48 to 65.
[0115] Polynucleotides, vectors, host cells, and production methods The anti-Ang-2 antibody and the multispecific fusion protein comprising the present invention can be produced by any antibody production technology and fusion protein production technology known in the art.
[0116] Another aspect of the present invention provides a polynucleotide encoding a single-domain antibody (sdAb) that specifically binds to Ang-2 or an antigen-binding fragment thereof, or a multispecific fusion protein comprising the thereof.
[0117] The definitions of “angiopoietin-2”, “antibody”, “sdAb”, “single-domain antibody that specifically binds to angiopoietin-2”, and “multispecific fusion protein” are as described above.
[0118] These polynucleotide molecules may encode the heavy chain variable region or heavy chain CDR region of an anti-Ang-2 antibody, or the amino acid sequence of a multispecific fusion protein. In one example, the sequence of the polynucleotide molecule encoding the heavy chain variable region and CDR region of the anti-Ang-2 antibody according to the present invention may be the polynucleotide sequences of SEQ ID NO: 70 to 79, see Table 4. In one example, the sequence of the polynucleotide molecule encoding the fusion protein according to the present invention may be the polynucleotide sequences of SEQ ID NO: 80 to 97.
[0119] The term "polynucleotide" has a broad meaning encompassing both DNA (gDNA and cDNA) and RNA molecules, and is also used interchangeably with "nucleic acid molecule." Nucleotides, which are the basic building blocks of polynucleotides, include not only natural nucleotides but also analogs in which the sugar or base portions are modified. The sequences of polynucleotides encoding the anti-Ang-2 antibody of the present invention and fusion proteins comprising thereof can be modified. Modifications include the addition, deletion, or non-conserved or conserved substitution of nucleotides. The polynucleotides of the present invention should be interpreted as including nucleotide sequences that exhibit substantial identity with the nucleotide sequence. Substantial identity means a nucleotide sequence that, when aligned with the nucleotide sequence of the present invention to the greatest extent possible and analyzed using algorithms commonly used in the art, exhibits 80% or more homology (90% or more homology in one particular example, 95% or more homology in another particular example, and 98% or more homology in yet another particular example).
[0120] Another aspect of the invention provides one or more expression vectors comprising polynucleotides. The definition of "polynucleotide" is as described above.
[0121] "Vector" refers to a nucleic acid molecule capable of carrying another nucleic acid linked to it. One type of vector is a "plasmid," which is a circular double-stranded DNA loop into which an additional DNA segment can be inserted. Another type of vector is a viral vector, in which a DNA or RNA sequence derived from a virus is present for packaging into a virus. Some vectors can replicate autonomously in the host cell to which they are to be introduced (e.g., bacterial vectors with bacterial origins of replication and free mammalian vectors). When other vectors (e.g., non-free mammalian vectors) are introduced into the host cell, they can integrate into the host cell's genome and replicate accordingly with the host genome. Furthermore, some vectors can induce the expression of genes operatively linked to them. Such vectors are referred to as "expression vectors" in this specification. Commonly used expression vectors in recombinant DNA technology are typically in the form of plasmids. In this specification, "plasmid" and "vector" are used interchangeably because plasmids are the most commonly used form of vector. However, this invention aims to include other forms of expression vectors with equivalent functionality, such as viral vectors (e.g., replication-defective retroviruses, adenoviruses, and adeno-associated viruses).
[0122] Another aspect of the invention provides a host cell comprising an expression vector. In particular, the definition of "expression vector" is as described above.
[0123] The host cell can be a cell transformed with the recombinant vector of the present invention. Any host cell known in the art capable of achieving stable, continuous cloning and expression of the recombinant vector can be used. In one example, the host cell can be a prokaryotic, yeast, or eukaryotic cell. In one example, suitable prokaryotic host cells include *Escherichia coli*, *Bacillus* strains (e.g., *Bacillus subtilis*). Bacillus subtilis ) and Bacillus thuringiensis ( Bacillus thuringiensis ), and intestinal bacteria and strains (such as Salmonella typhimurium) Salmonella typhimurium Serratia marcescens ( ), Serratia marcescens (and various Pseudomonas strains). Suitable eukaryotic host cells for transformation include yeast (e.g., Saccharomyces cerevisiae). Saccharomyces cerevisiae ( ), insect cells, plant cells, and animal cells (e.g., Sp2 / 0, Chinese hamster ovary (CHO) K1, CHO DXB-11, CHO DG44, PER.C6, CHO / -DHFR, HEK293, HEK293F, VERO, HELA, BRL 3A, SP2 / 0, NS-0, WI38, BHK, COS-7, 293, HepG2, Huh7, 3T3, RIN, and MDCK cell lines). Furthermore, the term "host cell" is used to refer to transformed cells or cells transformed with nucleic acid sequences and capable of expressing the selected target gene. This term includes offspring of parental cells, regardless of whether the offspring are morphologically or genetically identical to the original parent, provided the selected gene is present.
[0124] Another aspect of the present invention provides a method for producing antibodies or fusion proteins, comprising culturing the host cells.
[0125] Culture of host cells used for the production of antibodies, their antigen-binding fragments, and multispecific fusion proteins comprising them can be performed using suitable culture media and conditions known in the art. Such culture processes can be readily adapted to the selected host cells and are usable by those skilled in the art. Culture processes are classified as suspension culture and adherent culture according to the type of cell growth, and as batch, fed-batch, and continuous culture according to the culture type. Various culture processes are disclosed, for example, in the literature [“Biochemical Engineering” by James M. Lee, Prentice-Hall International Editions, pp 138-176].
[0126] In one example, culture can be performed using CHO cells and any commercially available culture medium without limitation. Culture temperature, pH, feeding frequency, time, etc., can be appropriately adjusted for the selected host cells, and protein expression and cell culture steps can be performed using transient or stable expression systems with specialized culture conditions, as will be apparent to those skilled in the art. The antibodies and multispecific fusion proteins of this invention, due to their stable sequences and structures, possess the characteristic of achieving high-efficiency expression of at least 300 mg per liter of culture medium, even under the transient expression conditions of the examples.
[0127] In one embodiment, the method for producing an antibody or fusion protein may further include recovering the antibody or fusion protein from cultured cells.
[0128] To recover antibodies, any method known in the art for immunoglobulin purification can be used, such as chromatography (ion exchange, affinity (e.g., protein A), hydrophobicity, size exclusion, etc.), centrifugation, differential solubility, or other standard techniques for protein purification.
[0129] In one example, recovery may involve removing cells, for example, by filtration to obtain harvested cell culture medium (HCCF), and performing a first purification step on the resulting product by protein A affinity chromatography. In one embodiment, it has been confirmed that the antibodies of the present invention and the multispecific fusion proteins comprising them, when subjected to a single purification step of protein A affinity chromatography, exhibit an average purity of about 97% or higher by SE-HPLC analysis due to their stable sequence and structure. That is, the antibodies of the present invention or the fusion proteins comprising them can be recovered by a single-step protein A affinity chromatography process with an average of 300 mg or more of fusion protein per liter of culture medium and a purity of 98% or higher. This is because the antibodies or fusion proteins of the present invention have excellent physicochemical properties, allowing for the easy recovery of high quantities of protein by a single step of purification using only conventional methods in the art, thereby facilitating the production of highly concentrated formulations.
[0130] The anti-Ang-2 antibody or fusion protein comprising thereof of the present invention has been confirmed to be highly recoverable from culture supernatant in high yield and high purity, even in CHO cells using only a transient expression system and a protein A affinity chromatography step, due to the stability of its physical properties. In one example, the anti-Ang-2 antibody of the present invention exhibits high thermostability, resulting in a high aggregation temperature comparable to that of conventional antibodies, thus demonstrating excellent physicochemical properties. Considering common knowledge in the art that fusion proteins are generally difficult to express and have a high probability of protein aggregate formation and low molecular weight fragment formation, the ability of the antibody or fusion protein comprising thereof of the present invention to produce proteins in high concentrations and high purity formulations is of significant importance.
[0131] Pharmaceutical Composition Another aspect of the present invention provides a pharmaceutical composition for the prevention or treatment of diseases associated with Ang-2 activation or overexpression, comprising, as an active ingredient, a single-domain antibody of the present invention that specifically binds to Ang-2, an antigen-binding fragment thereof, or a multispecific fusion protein.
[0132] The definitions of “angiopoietin-2”, “antibody”, “sdAb”, “single-domain antibody that specifically binds to angiopoietin-2”, and “multispecific fusion protein” are as described above.
[0133] As used in this article, the term "diseases associated with Ang-2 activation or overexpression" is interpreted as a general term for diseases caused by abnormal activation or excessive production of the Ang-2 protein. Under normal conditions, the expression level of Ang-2 is in balance with that of Ang-1, but in various vascular diseases, an imbalance occurs in which the Ang-2 level is relatively higher.
[0134] Specifically, diseases associated with Ang-2 activation or overexpression can be vascular diseases, and more specifically, can include diseases associated with angiogenesis, diseases associated with vascular endothelial cell stabilization, and / or diseases associated with vascular permeability.
[0135] In one example, diseases associated with Ang-2 activation or overexpression may include, but are not limited to, age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR), retinal vein occlusion (RVO), retinopathy of prematurity (ROP), neovascular glaucoma, proliferative retinopathy, vascular adhesion, Clarkson's disease (ISCLS), osteoarthritis, rheumatoid arthritis, psoriasis, Crohn's disease, ulcers, diabetic nephropathy, nephritis, cirrhosis, neurodegenerative diseases, or atherosclerosis.
[0136] The anti-Ang-2 antibody of the present invention binds to Ang-2 with high affinity, thereby inhibiting and / or neutralizing the activity of the Ang-2 protein. Therefore, it is highly practical for the prevention or treatment of diseases in which Ang-2 protein is activated or overexpressed. In one embodiment, the excellent Ang-2 binding affinity and inhibitory ability of the anti-Ang-2 antibody of the present invention on phosphorylation signaling in the TEK / Tie2 pathway have been confirmed, and therefore, its significant inhibitory ability on angiogenesis in actual animal models has been confirmed, and it can be advantageously used for the treatment of diseases associated with Ang-2 activation or overexpression.
[0137] As used herein, the term “prevention” can mean any action by applying the composition to inhibit or delay the onset of a disease associated with angiopoietin-2 activation or overexpression, and the term “treatment” can mean any action by applying the composition to improve or beneficially alter the symptoms of a disease.
[0138] The pharmaceutical composition may further include a pharmaceutically acceptable carrier.
[0139] As used herein, the term "pharmaceutically acceptable carrier" refers to a carrier or diluent that does not irritate the organism and does not impair the biological activity and properties of the applied compound. For compositions formulated into liquid solutions, acceptable pharmaceutical carriers are those that are sterile and biocompatible, including saline solutions, sterile water, Ringer's solution, buffered saline solutions, albumin injections, glucose solutions, maltodextrin solutions, glycerol, ethanol, and one or more mixtures of these components, and may be supplemented with other conventional additives such as antioxidants, buffers, and antibacterial agents as needed. Furthermore, by adding diluents, dispersants, surfactants, binders, and lubricants, they can be formulated into injectable formulations such as aqueous solutions, suspensions, and emulsions, as well as pills, capsules, granules, or tablets.
[0140] Pharmaceutical compositions can be various oral or parenteral formulations. During formulation, diluents or excipients such as common fillers, expanders, binders, wetting agents, disintegrants, and surfactants are used. Solid dosage forms for oral administration include tablets, pills, powders, granules, capsules, etc., which are prepared by mixing at least one excipient (e.g., starch, calcium carbonate, sucrose or lactose, gelatin, etc.) with one or more compounds. In addition to simple excipients, lubricants such as magnesium stearate and talc are used. Liquid dosage forms for oral administration include suspensions, oral liquid formulations, emulsions, syrups, etc., and may include various excipients such as wetting agents, sweeteners, flavoring agents, and preservatives, in addition to common simple diluents such as water and liquid paraffin. Dosage forms for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized formulations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate can be used as non-aqueous solvents and suspension solvents. As a base for suppositories, Wipedesol, Macrogol, Tween 61, cocoa butter, lauryl ester, glycerin gelatin, etc. can be used.
[0141] The pharmaceutical composition may be selected from any one of the following formulations: tablets, pills, powders, granules, capsules, suspensions, oral liquid formulations, emulsions, syrups, sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized formulations, and suppositories.
[0142] The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount.
[0143] As used herein, the term "pharmaceuticalally effective amount" refers to an amount sufficient to treat a disease with a reasonable benefit / risk ratio suitable for medical treatment. The level of an effective dose can be determined based on factors including subject type, disease severity, age, sex, disease type, drug activity, drug sensitivity, time of administration, route of administration, excretion rate, duration of treatment, combination therapy, and other factors well known in the medical field. The compositions of the present invention can be administered as a standalone treatment or in combination with other treatments, and can be administered sequentially or simultaneously with conventional treatments. The compositions of the present invention can be administered in single or multiple doses. It is important to administer the minimum effective amount that maximizes efficacy without causing side effects while taking all the above factors into account, and this amount can be readily determined by those skilled in the art.
[0144] The pH of the pharmaceutical composition can be from pH 4 to 8, and more specifically, it can exhibit high stability at pH 4.8 to 5.7, pH 4.5 to 5.5, pH 5 to 5.7, pH 5 to 5.5, pH 7 to 8, pH 7 to 7.8 or pH 7.2 to 7.5.
[0145] As described above, the anti-Ang-2 antibody or fusion protein of the present invention is readily produced as a highly concentrated and pure formulation due to its excellent physical properties, thus providing advantageous benefits, for example, in providing a volume-limited pharmaceutical composition for IVT injection. In one example, the pharmaceutical composition of the present invention can be provided as a formulation comprising a highly concentrated active ingredient of 100 mg / mL or higher.
[0146] In one embodiment, the pharmaceutical composition may include a fusion protein containing both an anti-Ang-2 antibody and an anti-VEGF antibody as the active ingredient. In such cases, the pharmaceutical composition can exhibit excellent efficacy in treating vascular diseases by inhibiting both Ang-2 and VEGF. Anti-VEGF therapy alone can lead to choroidal ischemia due to excessive inhibition of angiogenesis, and there may be concerns about serious side effects, for example, in elderly or diabetic patients requiring angiogenesis in ischemic brain, heart, or limbs. Therefore, the pharmaceutical composition according to one embodiment of the invention can simultaneously inhibit Ang-2 and VEGF, thereby exhibiting excellent efficacy in stabilizing and normalizing neovascularization without the side effects of anti-VEGF therapy. In this regard, the characteristic that the fusion protein of the invention can be readily formulated into highly concentrated and pure formulations allows for an increase in the amount of active ingredient contained in the same volume of composition. This provides a significant technical advantage in developing anti-VEGF therapeutics primarily formulated for intravitreal (IVT) injection.
[0147] Treatment Another aspect of the present invention provides a method for preventing or treating diseases associated with Ang-2 activation or overexpression, comprising administering a pharmaceutical composition to a subject.
[0148] "Pharmaceutical composition", "angiopoietin-2", "disease associated with angiopoietin-2 activation or overexpression", "treatment" or "prevention" are defined as above.
[0149] A method for treating a disease associated with angiopoietin-2 activation or overexpression may include administering a pharmaceutical composition comprising an antibody and a pharmaceutically acceptable carrier to a subject who has developed or is suspected of having a disease associated with angiopoietin-2 activation or overexpression, wherein the pharmaceutically acceptable carrier is as described above. Specifically, a method for treating a disease associated with angiopoietin-2 activation or overexpression may include administering a pharmaceutical composition comprising the anti-Ang-2 antibody of the present invention to a subject suffering from a disease associated with angiopoietin-2 activation or overexpression.
[0150] Subjects include mammals, including cattle, pigs, sheep, chickens, dogs, and humans, birds, etc., and include, without limitation, subjects who treat diseases by administering the compositions of the present invention.
[0151] In particular, the composition can be administered in a single or multiple doses at a pharmaceutically effective amount. Specifically, the composition can be administered in the form of liquid, powder, aerosol, capsule, enteric-coated tablet, capsule, or suppository. Routes of administration include, but are not limited to, intravitreal, intravenous, intramuscular, subcutaneous, endothelial, oral, topical, intranasal, pulmonary, and rectal administration. However, when administered orally, the peptide can be digested, therefore the oral composition must be formulated with a coating active agent or protected from degradation in the stomach. Furthermore, the pharmaceutical compositions of the present invention can also be administered via any device capable of transporting the active substance to target cells.
[0152] Therapeutic uses Another aspect of the invention provides the use of the composition in treating diseases associated with Ang-2 activation or overexpression.
[0153] "Pharmaceutical composition", "angiopoietin-2", "disease associated with angiopoietin-2 activation or overexpression" or "treatment" are defined as above.
[0154] Diagnostic methods Another aspect of the present invention provides a method for providing diagnostic information for vascular diseases, comprising detecting Ang-2 protein in isolated biological samples of a subject suspected of having vascular disease via an antigen-antibody reaction using an anti-Ang-2 antibody. Furthermore, this method can be used for diagnosing vascular diseases.
[0155] "Anti-Ang-2 antibody", "Ang-2", and "vascular disease" are defined as above.
[0156] A method for providing information or for diagnosing vascular diseases can detect Ang-2 protein by reacting an antibody specific to Ang-2 of the present invention with a subject suspected of having vascular disease or a separated biological sample of a subject with vascular disease, and detecting the formation of antigen-antibody complexes. In this way, the method can provide information for the diagnosis or prognostic prediction of vascular diseases.
[0157] Specifically, the method for providing information or for diagnosing vascular disease may include the following: (a) treating isolated biological samples of a subject suspected of having vascular disease with antibodies to detect Ang-2 protein by antigen-antibody reaction; and (b) comparing the level of Ang-2 protein detected in (a) with that of a control group, and if the level of Ang-2 protein is higher than that of the control group, then the subject is determined to be a patient with vascular disease.
[0158] As used herein, the term "biological sample" may include, but is not limited to, tissues, cells, whole blood, serum, plasma, autopsy tissue samples (brain, skin, lymph nodes, spinal cord, etc.), cell culture supernatants, ruptured eukaryotic cells, and bacterial expression systems. Such biological samples may react with the antibodies of this invention (in manipulated or unmanipulated form) to confirm the presence of Ang-2 protein or the presence or absence of vascular disease.
[0159] As used herein, the term "antigen-antibody complex" refers to a conjugate of an Ang-2 protein antigen in a sample with an anti-Ang-2 antibody that recognizes the antigen according to the present invention. The formation of such antigen-antibody complexes can be detected by any method selected from colorimetric, electrochemical, fluorescence, luminescence, particle counting, visual evaluation, and scintillation counting methods. However, it is not necessarily limited to the above and can be applied to a wide variety of applications and uses.
[0160] In this invention, various labeling agents can be used to detect antigen-antibody complexes. Specific examples may be selected from enzymes, fluorescent dyes, ligands, luminescent materials, microparticles, and radioisotopes, but are not limited thereto.
[0161] Specifically, antigen-antibody complexes can be detected using enzyme-linked immunosorbent assay (ELISA). ELISA includes various ELISA methods, such as: direct ELISA, which uses a labeled antibody that recognizes an antigen attached to a solid support; indirect ELISA, which uses a labeled secondary antibody that recognizes a capture antibody in an antigen-antibody complex attached to a solid support; direct sandwich ELISA, which uses another labeled antibody that recognizes the antigen in the antigen-antibody complex attached to a solid support; indirect sandwich ELISA, which involves reacting with another antibody that recognizes the antigen in the antigen-antibody complex attached to a solid support and using a labeled secondary antibody to recognize that antibody; competitive ELISA, in which different antigens having the same antibody binding site compete with each other, and so on.
[0162] [Methods of Implementing the Invention] Example 1: Screening anti-angiogenic factor-2 (Ang-2) antibodies from a phage display synthetic single-domain antibody library Example 1-1. Biopanning of phage libraries for screening Ang-2 specific antibodies For phage library panning, human Ang-2 protein was diluted to a concentration of 10 μg / mL in PBS, and 100 μL of this solution was added to each well of a 96-well microtiter plate (Cat. No. 32296, SPL, South Korea). The plate was coated at 4°C for 16 hours. After washing the coated plate with PBS, 100 μL of PBS containing 2% skim milk powder was added to each well, and the plate was blocked at 4°C for 12 hours, followed by washing three times with PBS.
[0163] For the first round of selection, 70 μL of phage solution (in 2% BSA / 0.1% Tween-20 at a concentration of 4 × 10⁻⁶) was used. 12 Phage ( / mL) was added to an Ang-2-coated microtiter plate and incubated at 37°C for 1 hour. The plate was then washed 15 times with PBST (0.1% Tween 20 / PBS, 200 μL), followed by an additional 5 washes with PBS. Starting with the second round of panning, the number of PBST washes was increased with each panning round. Antibodies binding to Ang-1 were removed by adding 1 μg of Ang-1 protein to each well. After washing, bound phages were eluted by adding 50 μL of PBS containing 5 μg of HRV 3C protease to each well and allowing the reaction to proceed at room temperature for 3 hours. The eluted phages were used to infect 100 μL of 2xTY medium containing 10 μg / mL tetracycline until OD. 600nmThe XL1-Blue bacteria reached a concentration of 0.5. After incubating at 37°C for 1 hour, the medium was replaced with LB medium containing 100 μg / mL ampicillin, and the culture was incubated at 37°C for 16 hours or longer.
[0164] The following day, the culture was infected with VCSM13-assisted phages, and *E. coli* was incubated in LB medium containing 100 μg / mL ampicillin and 50 μg / mL kanamycin to generate phages. 1 mL of culture was centrifuged at 3,500 rpm for 10 min, and the supernatant was transferred to a new tube. Then, 0.25 mL of 20% PEG / 2.5 M NaCl solution was added, mixed, and allowed to react on ice for 1 h. Phage particles were precipitated by centrifugation at 12,000 rpm for 15 min at 4 °C. For the next round of panning, the phage pellet was resuspended in 70 μL of PBST containing 2% skim milk powder / 0.1% Tween-20. The same procedure was performed on two synthetic single-domain antibody phage libraries (Library A and Library B).
[0165] Examples 1-2. Obtaining single clones by enzyme-linked immunosorbent assay (ELISA) 200 μL of phage-infected cells were washed with a final round of panning and centrifuged. The resulting pellet was resuspended in 100 μL of PBS, lysed by sonication, and centrifuged to collect only the supernatant. 4 μL of the supernatant was reacted with anti-mouse IgG HRP (horseradish peroxidase) secondary antibody (Cat. No. A9169, Sigma) diluted 1:5,000 in 100 μL PBS / 0.1% Tween-20 on an Ang-2-coated microtiter plate at room temperature for 1 hour. To confirm specificity for Ang-2, the same reaction was performed on a microtiter plate coated with Ang-1 protein, a homologous protein with high sequence homology to Ang-2. After washing five times with PBST (PBS / 0.1% Tween-20), the cells were developed with 3,3',5,5'-tetramethylbenzidine (TMB) substrate at room temperature for 10 minutes, and the color development was confirmed. To select specific single clones, the cells from the final round of panning were diluted and plated on LB agar plates containing ampicillin. From the final expanded libraries, 192 colonies (384 single colonies in total) were selected from phage libraries A and B, respectively, and inoculated into 1 mL of LB medium, followed by incubation at 37°C and 200 rpm for 18 hours with shaking. 1 mL of each culture was centrifuged, and the resulting precipitate was resuspended in 100 μL PBS and analyzed by ELISA as described above. After color development, TMB stop solution was added, and absorbance was measured at 450 nm using a TECAN spectrometer. Single clones exhibiting high reactivity to Ang-2 and low reactivity to Ang-1 were selected. The number of clones obtained through this process is shown in Table 1.
[0166] [Table 1] The selected clones were subjected to PCR to confirm the individual nucleotide sequences, thereby obtaining the amino acid sequences of the Ang-2-specific single-domain antibodies (sdAbs), as shown in Table 2 below. Furthermore, the CDR sequences of the obtained single-domain antibodies, based on Kabat numbering, are shown in Table 3. Additionally, the nucleotide sequences of the single-domain antibodies are shown in Table 4.
[0167] [Table 2] *sdAb: Single-domain antibody [Table 3] [Table 4] Examples 1-3. Gene cloning of Ang-2 specific sdAbs HF PCR premix and forward and reverse primers were used to directly PCR the culture media of each clone to obtain the Ang-2 specific antibody gene. The amplified gene was analyzed on a 1% agarose gel to confirm the predicted DNA band size, and then isolated using a gel extraction kit. The isolated gene was inserted into a bacterial expression vector expressing the streptococcal protein GB1 domain (SEQ ID NO: 46) with 18 bp homologous regions at both ends, or into a bacterial expression vector expressing the rabbit immunoglobulin Fc fragment (crystallizable region of the rabbit IgG fragment) (SEQ ID NO: 47), using overlap PCR. The ligation reaction mixture was transformed into XL1-Blue bacteria, and the transformed bacteria were inoculated onto LB agar plates containing ampicillin and incubated at 37°C for 12 hours or longer. Single colonies were cultured, plasmids were isolated, and then transformed into antibody-expressing strains.
[0168] Examples 1-4. Production of Ang-2 specific sdAbs To produce and purify antibody clones obtained from the phage library, purification was performed using immobilized metal affinity chromatography (IMAC). Expression vectors were transformed into the BL21 (LysS) strain, and colonies were inoculated into 1 L of LB medium containing ampicillin and cultured. 1 mL of culture was collected, centrifuged, resuspended in 2X sample buffer, and subjected to SDS-PAGE to confirm target protein expression. The entire culture medium containing the confirmed target protein was centrifuged to obtain a cell pellet, which was resuspended in binding buffer (20 mM Tris-HCl, pH 7.9, 500 mM NaCl, 40 mM imidazole). Cells were disrupted using an ultrasonic homogenizer and centrifuged at 12,000 rpm, collecting the supernatant to obtain a whole-cell extract. The whole-cell extract was loaded onto a Ni-iminodiacetic acid-linked resin. The resin was washed three or more times with washing buffer (20 mM Tris-HCl, pH 7.9, 500 mM NaCl, 40 mM imidazole). After washing, the target protein was eluted using elution buffer. The elution buffer consisted of 20 mM Tris-HCl, pH 7.5, 100 mM NaCl, and 60 mM imidazole; elution was performed by stepwise increases in imidazole concentration (60, 100, 250, and 500 mM) to obtain the respective elution fractions. Protein content was quantified for each fraction using the Bradford method. Fractions containing protein were analyzed by SDS-PAGE, and elution fractions containing only the target protein were combined. PBS buffer exchange was performed using an Amicon stirred cell system (10K MWCO, Cat. No. UFSC05001, Merck, USA). The purified protein was then stored at a concentration of 1 mg / mL in PBS containing 50% glycerol. Protein electrophoresis was performed under reducing and non-reducing conditions to finally validate the concentration and conditions. The protein was stored at -20°C, and the results are shown below. Figure 1 middle.
[0169] Through the above process, 10 anti-Ang-2 single-domain antibodies were developed, and anti-Ang-2 single-domain antibodies fused with GB1 and Fc respectively were finally obtained to achieve stability in expression and production.
[0170] Example 2. Analysis of direct binding of anti-Ang-2 single-domain antibody to Ang-1 and Ang-2 To analyze the direct binding of the single-domain antibody obtained in Example 1 to Ang-1 and Ang-2, a direct binding ELISA was performed.
[0171] 96-well Maxibinding plates (SPL) were coated with 2 μg / mL human Ang-2 antigen or human Ang-1 antigen (R&D Systems). The plates were washed five times with PBST (PBS containing 0.1% Tween-20) and then blocked with PBS containing 2% skim milk powder at room temperature. Prepared sdAb-GB1 and sdAb-Fc were added to each well of the antigen-coated plate at concentrations ranging from 0.01 μg / mL to 1 μg / mL, and allowed to react for 1 hour at room temperature. After washing five times with PBST (PBS containing 0.1% Tween-20), HRP-conjugated anti-mouse IgG antibody (Sigma) was added to each well and reacted at room temperature. Finally, 100 μL of TMB substrate (SeraCare) was added to each well to induce color development for 30 minutes, and the reaction was terminated with 1 M H2SO4 solution. The OD was measured using a Molecular Devices microplate spectrophotometer. 450nm The absorbance was measured at the point.
[0172] As a result, the specific binding (EC50) of the GB1-fusion anti-Ang-2 single-domain antibody (sdAb-GB1) to Ang-1 and Ang-2 antigens, as determined by ELISA titration, was shown in... Figure 2 The specific binding (EC50) of the Fc-fusion anti-Ang-2 single-domain antibody (sdAb-Fc) to Ang-1 and Ang-2 antigens, as determined by ELISA titration, is shown in the figure. Figure 3 middle.
[0173] Example 3. Analysis of the effect of anti-Ang-2 single-domain antibody on the competitive binding of Ang-1 and Ang-2 to TEK / Tie2. To analyze the inhibitory activity of the anti-Ang-2 domain on the binding of Ang-2 to the TEK / Tie2 receptor and its selectivity for Ang-1, a competitive ELISA was performed using the single-domain antibody obtained in Example 1, wherein the competitive binding (IC50) of biotinylated antigen proteins (biotinylated Ang-1 and biotinylated Ang-2) to the TEK / Tie2 receptor was measured in the presence of the antibody of the present invention.
[0174] Specifically, 96-well MaxiSorp was coated with hTie2-Fc (R&D Systems) at a concentration of 100 ng / well. TMFlat-bottomed plates (Nunc). Next, the plates were washed three times with PBST (phosphate-buffered saline, 0.05% Tween-20) and then blocked with TBS (Tris-buffered saline) containing 1% (v / v) BSA (bovine serum albumin; Sigma) at room temperature for 2 hours. The prepared anti-Ang-2sdAb-GB1 antibody and anti-Ang-2 sdAb-Fc antibody were each reacted with biotinylated Ang-1 or biotinylated Ang-2 at various concentrations from a maximum of 1 μM to 0.01 pM at room temperature for 2 hours to induce binding. The reaction mixture of sdAb and biotinylated antigen protein (Ang-1 or Ang-2) was added to each well coated with hTie2-Fc-fusion protein and allowed to react at room temperature for 2 hours, then the plates were washed three times with PBST. Streptavidin-conjugated horseradish peroxidase (HRP) was added to the wells and allowed to react at room temperature for 1 hour, then washed three times with PBST. Finally, 100 μL of TMB (3,3',5,5'-tetramethylbenzidine) substrate (SeraCare) was added to each well of the plate to induce color development for 30 minutes, and then the reaction was terminated with 1M H2SO4 solution. OD was measured using a microplate absorbance reader (Molecular Devices). 450nm value.
[0175] As a result, the competitive binding (IC50) of the anti-Ang-2 sdAb-GB1 antibody to Ang-1 and Ang-2 is shown in Table 5, and the competitive binding (IC50) of the anti-Ang-2 sdAb-Fc antibody to Ang-1 and Ang-2 is shown in [reference needed]. It was confirmed that the anti-Ang-2 sdAb-GB1 antibody does not inhibit the binding of Ang-1 to Tie2. Regarding the inhibitory ability on the binding of Ang-2 to Tie2, different binding inhibition abilities (IC50) were observed depending on the anti-Ang-2 single-domain sequence, thus confirming that the discovered single-domain antibody sequences have excellent Ang-2-specific binding, despite high sequence homology between Ang-1 and Ang-2 antigens. In particular, sdAb-GB1 fused with the ALTS95B domain exhibited the highest inhibitory ability, with an IC50 of 0.424 nM (Table 5). It was also confirmed that the anti-Ang-2 sdAb-Fc antibody, like sdAb-GB1, does not inhibit the binding between Tie2 and Ang-1. In particular, sdAb-Fc fused with the ALTS59B domain showed the highest suppression capability, at 0.268 nM (Table 6).
[0176] [Table 5] *sdAb-Fc: Fc-fused single-domain antibody (sdAb) **NC: No Competition** [Table 6] Example 4. Analysis of the inhibitory activity of anti-Ang-2 single-domain antibody against TEK / Tie2 receptor signaling. Next, the inhibitory activity of the anti-Ang-2 single-domain antibody (sdAb-Fc) on TEK / Tie2 receptor signaling was analyzed. The anti-Ang-2 sdAb-Fc antibody obtained in Example 1 was used.
[0177] Human umbilical vein endothelial cells (HUVEC, Cell Systems) were suspended in endothelial cell culture medium (ECM) containing growth factors. Cells were cultured at a rate of 2 × 10⁶ cells per well. 5Cells were seeded into 6-well plates. After 1 day of culture, the medium was replaced with ECM containing 0.5% FBS (fetal bovine serum), and the cells were cultured for another 6 hours. Angiopoietin-2 (Ang-2, 500 ng / ml) and various concentrations of anti-Ang-2 Fc-fusion single-domain antibodies (hereinafter, antibodies) were premixed in ECM. The mixture was incubated for 30 minutes to induce Ang-2-antibody complex formation. The cells cultured in the 6-well plates were washed once with HBSS (Hank Balanced Salt Solution). Then, 1 mL of the Ang-2-antibody complex prepared from the reaction-terminating mixture was added to each well. The plates were incubated in a CO2 incubator for 30 minutes. After incubation, each well was washed once with HBSS. Cells were lysed with cell lysis buffer containing protease inhibitors and phosphatase inhibitors. Protein concentration was quantified using the BCA assay (Pierce). Equal volumes of total protein from all samples were immunoprecipitated overnight at 4°C using anti-Tie2 antibody (R&D Systems). Anti-TEK / Tie2 antibodies were isolated from the lysates using Dynabeads (Invitrogen), washed three times with PBS, and subjected to 6% SDS-PAGE. The lysates, after removing anti-TEK / Tie2, were then subjected to 8% SDS-PAGE to separate proteins by size. Proteins were transferred from the gel to nitrocellulose membranes (Millipore). The membranes were blocked at room temperature with blocking buffer (5% skim milk powder or 4% BSA in TBST) and then incubated overnight at refrigerated temperature with either anti-phosphotyrosine antibody (Millipore) or anti-phospho-Akt (protein kinase B and rac) antibody (Cell Signaling Technology). Based on the species of the primary antibody, the membranes were incubated with anti-IgG-HRP secondary antibody at room temperature for 1 hour. The membranes were washed three times with TBST at each step. Development was performed using an ECL kit (BioRad) with a Chemidoc device (ATTO), and quantification was performed using a CS4 analyzer program. After development, the membranes were treated with stripping buffer at 60°C for 60 minutes to remove antibodies and then blocked at room temperature for 1 hour. The membrane was then incubated with anti-TEK / Tie2 (R&D Systems) or anti-Akt (Cell Signaling Technology) primary antibody at room temperature for 1 hour, followed by incubation with the corresponding secondary antibody at room temperature for 1 hour, and then developed in the same manner. The degree of phosphorylation was determined using quantitative signal values from a CS4 analyzer and calculated as the ratio of phosphorylated Tie2 to total Tie2 (pTie2 / Tie2) and the ratio of phosphorylated Akt to total Akt (pAkt / Akt).
[0178] As a result, the TEK / Tie2 receptor signaling inhibitory activity analysis of the anti-Ang-2 single-domain antibody was shown in... Figure 4 To evaluate Ang-2-induced Tie2 and AKT phosphorylation, solvent-treated groups were used as negative controls (NC) and Ang-2-only treated groups were used as positive controls (PC) in each phosphorylation assay. When sdAb-Fc was co-treated at 2-fold molar concentration relative to the target protein Ang-2, all protein treatments except the ALTS3B sdAb-Fc treatment group inhibited pTie2 / Tie2 to NC levels or lower. Furthermore, all protein treatments except the ALTS54B sdAb-Fc treatment group inhibited pAkt / Akt to near-NC levels.
[0179] Example 5: Evaluation of the anti-angiogenic activity of anti-Ang-2 single-domain antibody in a laser-induced CNV model The anti-angiogenic activity of the generated anti-Ang-2 single-domain antibody was evaluated in a laser-induced choroidal neovascularization (CNV) mouse model. An anti-Ang-2 antibody was used, which was expressed in the following structure: one of the domains corresponding to sdAb of SEQ ID NO: 3 was fused to the C-terminus of Fc, assembled into a homodimer, and formed two antigen-binding sites.
[0180] For this purpose, laser photocoagulation was applied to four spots in each eye of 8-week-old male C57BL / 6J mice to induce Bruch's membrane rupture. Immediately after laser irradiation, the test substance was administered once intravitreally into the eye at a dose of 1 μL / eye.
[0181] On day 13 after CNV induction, the eyeballs were enucleated and fixed in 4% paraformaldehyde solution for 30 minutes. Subsequently, the choroid was dissected and incubated for 1 hour in a blocking solution containing 5% BSA, 5% normal goat serum, and 0.5% Tx-100, followed by overnight staining with fluorescently labeled isoglucosin GS-IB4 (Invitrogen). After washing with PBS, the choroid was laid flat on a glass slide and images were acquired using a fluorescence microscope (Olympus). The CNV area of each spot in the acquired images was quantitatively analyzed using ImageJ software (NIH). In the figures, the solvent group is normalized to 100%, and the experimental group is expressed as a percentage relative to the solvent group. As a representative example, the comparison results of the anti-Ang-2 antibody (Anti-Ang-2) of SEQ ID NO: 3 with the solvent group are shown in [Figure missing]. Figure 5 middle.
[0182] like Figure 5 As shown, the anti-Ang-2 antibody of the present invention exhibits significant anti-angiogenic activity, inhibiting angiogenesis by approximately 50% compared to the solvent group.
[0183] Example 6: Production of a multispecific fusion protein including anti-Ang-2 antibody Example 6-1. Sequence Synthesis The DNA fragments with the desired sequence according to the present invention are prepared according to GeneScript (Seoul, South Korea) specifications.
[0184] The basic methods of DNA manipulation are described in the following references: Sambrook et al., Molecular Cloning: A Laboratory Manual; Cold SpringHarbor Laboratory Press, Cold Spring Harbor, New York (1989). The following molecular biology reagents should be used according to the manufacturer's instruction manual.
[0185] Example 6-2. Construction and culture of expression vectors A DNA sequence encoding a multispecific fusion protein that simultaneously binds VEGF and Ang-2 was synthesized in expression cassette form by adding restriction enzyme (XhoI and NotI) sequences and a leader peptide sequence to a nucleotide sequence encoding amino acids of SEQ ID NO: 48 to 65 (which includes the anti-Ang-2 single-domain antibody sequence and aflibercept sequence according to the invention). The synthesized DNA sequence was introduced into pcDNA3.4 (Invitrogen) using the XhoI and NotI restriction enzymes to construct a fusion protein expression vector. The pcDNA3.4 vector containing the DNA of the multispecific fusion protein that simultaneously binds VEGF and Ang-2 was transiently expressed in the CHO-S cell line. The CHO-S host cell gene ExpiCHO was used. TM Expression System Kits (Gibco) and OptiPRO TM Gene introduction was performed using SFM (Gibco), and based on the CHO-S cell line and ExpiFectamine... TM The procedure should be performed according to the expression system guidelines of the CHO transfection kit. Specifically, cells with viability of 90% or higher and a viable cell concentration of 6 × 10⁶ should be used. 6 CHO-S cells / mL at ExpiCHO TM Incubate the cells in expression medium (Gibco) at 37°C, 80% humidity or higher, and 8% CO2 in a CO2 incubator. Add the prepared cells to the culture medium using Expifectamine CHO reagent and OptiPRO. TMSFM transiently transfected cells with an expression vector containing the fusion protein DNA at a rate of 0.8 μg per 1 mL culture volume. Following transfection, ExpiCHO feed was added within 18 to 22 hours according to guidelines, and expression was carried out for up to 8 days in a CO2 incubator at 32°C, 80% or higher humidity, and 5% CO2. After expression, the culture medium was separated into supernatant and cells by centrifugation.
[0186] Example 6-3. Purification of the fusion protein By using protein A column (HiScreen Fibro) TM The supernatant solution obtained by centrifugation was purified using affinity chromatography (PrismA, Cytiva). To purify the fusion protein, the column was equilibrated with 20 mM sodium phosphate and 150 mM NaCl (pH 7.0) buffer. After binding the fusion protein to the column, 5 column volumes (5 CV) or more of 20 mM Tris, 500 mM NaCl (pH 7.0) buffer and 20 mM sodium citrate (pH 6.0) buffer were introduced to remove impurities. After these steps, the affinity-bound protein was eluted with 20 mM sodium citrate (pH 3.5) buffer, and the eluted fusion protein was immediately neutralized to pH 7.0 to pH 7.4 using 1 M Tris-HCl solution.
[0187] As a result, the expression and purification results of the multispecific fusion protein of the anti-Ang-2 antibody were published in [Journal Name]. Figure 6 and Figure 7 middle.
[0188] like Figure 6 As shown, the anti-Ang-2 antibody according to the present invention exhibits highly favorable physical properties in terms of expression, purification and stability of the fusion protein in all cases, whether introduced in a modular form at the N-terminus or C-terminus of the fusion protein or in a monovalent or multivalent form, which is beneficial from the perspective of material commercialization and large-scale production. Figure 7 The results of expression, purification, and purity (SE-HPLC analysis) of three different forms of multi-fusion proteins and multivalent fusion proteins of the ALTS54B clone (SEQ ID NO: 7) in the anti-Ang-2 single-domain antibody sequence are shown. The anti-Ang-2 fusion protein according to the present invention is confirmed to maintain stable physical properties, and can be produced at high purity and high concentration regardless of the fusion position or number of anti-Ang-2 single-domain antibodies, due to its excellent thermal stability and excellent expression levels.
[0189] Examples 6-4. Concentrates and Formulations For the ALTS49AafC4 (SEQ ID NO: 50) in the produced anti-Ang-2 fusion protein, the ALTS49AafC4 (SEQ ID NO: 50) fusion protein purified and neutralized by protein A affinity chromatography was concentrated using a membrane filter (Centricon-100, Amicon) with a molecular weight cutoff of 100 kDa. Simultaneously, the buffers were changed to PBS buffer pH 7.4 (phosphate-buffered saline), PBS buffer pH 7.0 (phosphate-buffered saline), histidine buffer pH 5.0 (10 mM histidine-HCl, 7% sucrose, 0.03% Tween 20), histidine buffer pH 5.5 (10 mM histidine-HCl, 7% sucrose, 0.03% Tween 20), histidine buffer pH 6.0 (10 mM histidine-HCl, 7% sucrose, 0.03% Tween 20), or histidine buffer pH 6.5 (10 mM histidine-HCl, 7% sucrose, 0.03% Tween 20). Specifically, the concentrated protein was concentrated using an Amicon® Millipore centrifuge at 4000 rpm and 4°C, and the buffers were changed to PBS and histidine buffer using the centrifuge filter unit. The results of buffer changes after product concentration are shown in Table 7 below. Figure 8 middle.
[0190] As a result, the ALTS49AafC4 fusion protein exhibited stable concentrations of approximately 20 mg / mL to 30 mg / mL under minimal excipient conditions at pH 5.0 to pH 5.5 and pH 7.0 to pH 7.4. Following concentration and buffer replacement, the fusion protein was subjected to SDS-PAGE and SE-HPLC under reducing and non-reducing conditions. As a result, the concentrate and formulation were stable at pH 5.0, pH 5.5, and pH 7.4 with a purity of 99% or higher.
[0191] [Table 7] Example 7: Analysis of the direct binding performance of a multispecific fusion protein including an anti-Ang-2 antibody to VEGF-A165 The binding performance of the multispecific fusion protein, including the anti-Ang-2 antibody, produced in Example 6 to recombinant human VEGF-A165 was analyzed using a direct binding ELISA method. Specifically, recombinant human VEGF-A165 (R&D Systems) was coated into 96-well MaxiSorp... TMOn flat-bottomed plates (Nunc). Wash the coated plates three times with PBS (phosphate-buffered saline) containing 0.05% (v / v) Tween-20, then block with PBS containing 1% (v / v) BSA (bovine serum albumin) and sucrose at room temperature for 2 hours. Induce binding by reacting the multispecific fusion protein, including the anti-Ang-2 antibody, at various concentrations ranging from 33 nM to 1 pM at room temperature for 2 hours. After binding, wash the plates three times with PBST, then add HRP-conjugated anti-human Fc secondary antibody (Invitrogen) to each well and allow the reaction to proceed at room temperature for 1 hour. After the reaction, wash the plates three times with PBST and add 100 μL of TMB substrate (SeraCare) to each well to induce color development for 30 minutes. Finally, terminate the reaction with 1 M H2SO4 solution and measure the absorbance (OD) using a microplate reader (Molecular Devices). 450nm EC50 (half-maximum reactive concentration) values of the fusion protein concentration were analyzed using SoftMax (Molecular Devices).
[0192] As a result, the direct binding affinity (EC50) values of the multispecific fusion proteins comprising anti-Ang-2 antibodies according to SEQ ID NO: 48 to 65 of the present invention with recombinant human VEGF-A165 are shown in the figure. Figure 9 The changes in VEGF-A165 binding absorbance, based on variations in the concentration of the multispecific fusion protein including the anti-Ang-2 antibody, are shown in [the figure]. Figure 10 In the analysis, ALTS53AafC4 (SEQ ID NO: 51) and ALTS53AafC4 (SEQ ID NO: 52) showed EC50 values of 109 pM and 112 pM for VEGF-A165, respectively, and all other fusion proteins were confirmed to have EC50 values in the tens of pM range. These results confirm that all proteins fused with the anti-Ang-2 domain exhibit high binding affinity for VEGF-A165.
[0193] Example 8: Analysis of the competitive binding performance of a multispecific fusion protein including anti-Ang-2 antibody to VEGF receptor 1 (VEGFR1) on VEGF. Next, the inhibitory effect of the multispecific fusion protein, including the anti-Ang-2 antibody, generated in Example 6 on the binding of VEGF-A165 to the VEGF receptor was analyzed using a competitive binding ELISA method.
[0194] Specifically, 96-well MaxiSorp was coated with hVEGFR1-Fc-fusion protein (R&D Systems). TMFlat-bottomed plates (Nunc). The plates were then washed three times with PBS (phosphate-buffered saline) containing 0.05% (v / v) Tween-20, and then blocked for 2 hours at room temperature with blocking buffer containing 1% casein. Various concentrations of multispecific fusion protein, including anti-Ang-2 antibody, were allowed to react with biotinylated recombinant human VEGF-A165 (R&D Systems) for 2 hours at room temperature to induce binding. A mixture of anti-Ang-2 antibody-fused multispecific protein and biotinylated antigen protein was added to each well coated with recombinant human VEGFR1-Fc-fusion protein, and the plate was allowed to react for 2 hours at room temperature, followed by three washes with PBST. Streptavidin-conjugated HRP was added to the wells and allowed to react for 1 hour at room temperature, followed by three washes with PBST. Finally, 100 μL of TMB substrate (SeraCare) was added to each well to induce color development for 30 minutes, and the reaction was terminated with 1 M H2SO4 solution. OD was measured using a microplate reader (Molecular Devices). 450nm The IC50 (half-maximum inhibition concentration) of the fusion protein concentration was evaluated using SoftMax (Molecular Devices).
[0195] As a result, the IC50 of the anti-Ang-2 fusion multispecific protein of SEQ ID NO: 48 to 65 according to the present invention for competitive inhibition of the binding of biotinylated VEGF-A165 to recombinant human VEGF receptor 1 (VEGFR1) is shown in... Figure 11 The absorbance changes of the multispecific fusion protein, including the anti-Ang-2 antibody, and the competitive binding of VEGF receptor 1 (VEGFR1) to biotinylated VEGF-A165 are shown in the figure. Figure 12 Regarding the inhibitory effect on the binding of VEGF-A165 to VEGFR1, all multispecific fusion proteins, including the anti-Ang-2 antibody, showed strong competitive binding inhibition at the nM level (IC50).
[0196] Example 9: Analysis of the direct binding performance of a multispecific fusion protein including an anti-Ang-2 antibody to Ang-1 / Ang-2 Next, the binding performance of the multispecific fusion protein, including the anti-Ang-2 antibody, to Ang-1 and Ang-2 was analyzed using a direct binding ELISA method.
[0197] Specifically, recombinant human Ang-1 (R&D Systems) and recombinant human Ang-2 (R&D Systems) were respectively coated into 96-well MaxiSorp TMPlates were prepared on flat-bottomed (Nunc) plates. The coated plates were washed three times with PBS (phosphate-buffered saline) containing 0.05% (v / v) Tween-20, and then blocked with PBS containing 1% (v / v) BSA (bovine serum albumin) and sucrose at room temperature for 2 hours. Multispecific fusion proteins, including anti-Ang-2 antibody, were then treated with various concentrations diluted to up to 42 nM and allowed to react at room temperature for 2 hours to induce binding. After binding, the plates were washed three times with PBST, and HRP-conjugated anti-human Fc secondary antibody (Invitrogen) was added to each well, allowing the reaction to proceed for 1 hour at room temperature. After the reaction, the plates were washed three times with PBST, and 100 μL of TMB substrate (SeraCare) was added to each well to induce color development for 30 minutes. Finally, the reaction was terminated with 1 M H2SO4 solution, and OD was measured using a microplate reader (Molecular Devices). 450nm The EC50 (half-maximum reactive concentration) values of the fusion protein concentration were analyzed using SoftMax (Molecular Devices).
[0198] As a result, the binding affinity of the multispecific fusion protein comprising anti-Ang-2 antibody of SEQ ID NO: 48 to 65 according to the present invention to recombinant human Ang-2 or Ang-1 is shown in EC50. Figure 13 ), and based on the concentration changes of the multispecific fusion protein including the anti-Ang-2 antibody, the changes in absorbance at binding to Ang-2 or Ang-1 are shown in Figure 14 The binding affinity (EC50) to Ang-2 was found to be strong, reaching several hundred pM. All fusion proteins exhibited minimal nonspecific binding to Ang-1, confirming high binding selectivity for the Ang-2 antigen.
[0199] Example 10: Analysis of the competitive binding performance of a multispecific fusion protein including an anti-Ang-2 antibody to Ang-2 with the TEK / Tie2 receptor. The inhibitory performance of the multispecific protein fusion of the anti-Ang-2 antibody against the TEK / Tie2 receptor was analyzed using competitive binding ELISA to examine its ability to competitively bind to Ang-2 or Ang-1.
[0200] Specifically, 96-well MaxiSorp was coated with recombinant human Tie2-Fc (R&D Systems). TMFlat-bottomed plates (Nunc). The plates were then washed three times with PBS (phosphate-buffered saline) containing 0.05% (v / v) Tween-20, and then blocked for 2 hours at room temperature with blocking buffer containing 1% casein. Various concentrations of multispecific fusion proteins, including anti-Ang-2 antibody, were reacted with biotinylated recombinant human Ang-1 or biotinylated recombinant human Ang-2 (R&D Systems) for 2 hours at room temperature to induce binding. A mixture of anti-Ang-2 antibody-fused multispecific protein and biotinylated antigen protein was added to each well coated with TEK / Tie2-Fc fusion protein, and the plate was incubated at room temperature for 2 hours, followed by three washes with PBST. Streptavidin-conjugated HRP was added to the wells and allowed to incubate for 1 hour at room temperature, followed by three washes with PBST. Finally, 100 μL of TMB substrate (SeraCare) was added to each well to induce color development for 30 minutes, and the reaction was terminated with 1 M H2SO4 solution. OD was measured using a microplate reader (Molecular Devices). 450nm The IC50 (half-maximum inhibition concentration) of the fusion protein concentration was analyzed using SoftMax (Molecular Devices).
[0201] As a result, the IC50 of the anti-Ang-2 fusion multispecific protein of SEQ ID NO: 48 to 65 according to the present invention competitively inhibits the binding of recombinant human TEK / Tie2-Fc protein to biotinylated Ang-2 is shown in... Figure 15 The absorbance changes in the competitive inhibition of biotinylated Ang-2 binding to TEK / Tie2, based on the concentration changes of the multispecific fusion protein including the anti-Ang-2 antibody, are shown in the figure. Figure 16 In the cases of SEQ ID NO: 48, 49, 50, 52, 53, and 54, very strong competitive binding inhibition (IC50) at the tens of pM level against Tie2 / Ang-2 was observed, while the remaining fusion protein sequences showed an IC50 at the nM level. Overall, it was confirmed that the greater the sdAb equivalent of the fusion, the stronger the competitive binding due to the affinity effect on the antigen, and that the competitive binding inhibitory activity was maintained regardless of whether the fusion site was at the N-terminus or the C-terminus.
[0202] Example 11: Analysis of the inhibitory activity of a multispecific fusion protein including anti-Ang-2 antibody on TEK / Tie2 receptor signaling in HUVEC cells. The inhibitory activity of a multispecific fusion protein, including an anti-Ang-2 antibody, on TEK / Tie2 receptor signaling in HUVEC cells was analyzed.
[0203] Human umbilical vein endothelial cells (HUVEC, Cell Systems) were suspended in endothelial cell culture medium (ECM) containing growth factors. Cells were cultured at a rate of 2 × 10⁶ cells per well. 5 Cells were seeded into 6-well plates. After 1 day of culture, the medium was replaced with ECM containing 0.5% FBS (fetal bovine serum), and the cells were cultured for another 6 hours. Angiopoietin-2 (Ang-2; 500 ng / mL) and various concentrations of the fusion proteins of SEQ ID NO: 54, SEQ ID NO: 60, SEQ ID NO: 63, and SEQ ID NO: 64 were premixed in ECM and allowed to react for 30 minutes to form Ang-2-antibody complexes. The cells cultured in the 6-well plates were washed once with HBSS (Hank Balanced Salt Solution). Then, 1 mL of the Ang-2-antibody complex prepared from the mixture at the end of the reaction was added to each well. The plates were incubated in a CO2 incubator for 30 minutes. After incubation, each well was washed once with HBSS. Cells were lysed with cell lysis buffer containing protease inhibitors and phosphatase inhibitors. Protein concentrations were quantified using the Pierce assay (BCA). Equal volumes of total protein from all samples were immunoprecipitated overnight at 4°C using anti-TEK / Tie2 antibody (R&D Systems). Anti-TEK / Tie2 antibody was isolated from the lysates using Dynabeads (Invitrogen), washed three times with PBS, and then subjected to 6% SDS-PAGE to isolate TEK / Tie2 protein. Cell lysates after Dynabeads removal were subjected to 8% SDS-PAGE to isolate Akt protein. Proteins were transferred from gels to membranes using nitrocellulose membranes (Millipore), blocked with blocking buffer (5% skim milk powder or 4% BSA in TBST) at room temperature, and each membrane was immunoblotted at refrigerated temperature using anti-phosphotyrosine antibody (Millipore) and anti-phospho-Akt antibody (Cell Signal Technology). Based on the species of the primary antibody, the membranes were incubated with anti-IgG-HRP secondary antibody at room temperature for 1 hour. Membranes were washed three times with TBST at each step. Developed using an ECL kit (BioRad) with a Chemidoc instrument (ATTO), and quantified using a CS4 analyzer program. After development, the membrane was incubated with stripping buffer at 60°C for 20 minutes to remove antibodies, followed by blocking at room temperature for 1 hour. The membrane was then incubated with anti-TEK / Tie2 (R&D Systems) or anti-Akt (Cell Signaling Technology) primary antibody at room temperature for 1 hour, followed by incubation with the corresponding secondary antibody at room temperature for 1 hour, and then developed in the same manner. Quantification was performed based on the signal values calculated by the CS4 analyzer.
[0204] As a result, the inhibitory activity of the multispecific fusion protein containing the anti-Ang-2 antibody against TEK / Tie2 receptor signaling in HUVEC cells was demonstrated. Figure 17 and Figure 18 middle.
[0205] Figure 17 The results show that when HUVEC cells are treated with the target protein Ang-2 and the fusion proteins of SEQ ID NO: 54, SEQ ID NO: 60 and SEQ ID NO: 64 according to the present invention at a 1:1 molar ratio, Ang-2-induced TEK / Tie2 receptor phosphorylation (PC in the left figure) and its downstream signal Akt phosphorylation (PC in the right figure) are inhibited to the level of the solvent-treated group (NC).
[0206] In addition, the minimum effective concentrations of the fusion proteins SEQ ID NO:54, SEQ ID NO:60, SEQ ID NO:63 and SEQ ID NO:64 that inhibit Ang-2-induced TEK / Tie2 and Akt phosphorylation to NC levels were confirmed. Figure 18 The results showed that when the fusion proteins of SEQ ID NO: 54, SEQ ID NO: 60, SEQ ID NO: 63 and SEQ ID NO: 64 were treated with 0.28, 0.50, 0.28 and 0.25 times the Ang-2 molar ratio, respectively, the phosphorylation of both TEK / Tie2 and Akt was inhibited to the NC level.
[0207] The above results confirm the excellent inhibitory effect of the fusion protein of the present invention on TEK / Tie2 receptor phosphorylation and Akt phosphorylation.
[0208] Example 12: Analysis of the enhancement of Ang-1-mediated HUVEC Akt phosphorylation activity by anti-Ang-2 / VEGF antibody fusion multispecific protein through inhibition of Ang-2 and VEGF. Human umbilical vein endothelial cells (HUVEC, Cell Systems) were suspended in endothelial cell culture medium (ECM) containing growth factors. Cells were cultured at a rate of 3 × 10⁶ cells per well. 5Cells were seeded into 6-well plates. After 1 day of culture, the medium was replaced with ECM containing 0.5% FBS (fetal bovine serum), and the cells were cultured for another 6 hours. Ang-1 (100 ng / mL), Ang-2 (500 ng / mL), VEGF (10 ng / mL), and various concentrations of multispecific fusion proteins, including anti-Ang-2 and anti-VEGF antibodies, were premixed in ECM and incubated for 30 minutes to allow for the formation of the VEGF-antibody-Ang-2 complex. The cells cultured in the 6-well plates were washed once with HBSS (Hank Balanced Salt Solution). Then, 1 mL of the Ang-2-antibody complex prepared from the reaction termination mixture was added to each well. The plates were incubated in a CO2 incubator for 30 minutes. After incubation, each well was washed once with HBSS. Cells were lysed with cell lysis buffer containing protease inhibitors and phosphatase inhibitors. Protein concentration was quantified using a BCA assay (Pierce), and cell lysates adjusted to have the same total protein content were subjected to 8% SDS-PAGE to separate Akt protein. Protein was transferred from the gel to the membrane using a nitrocellulose membrane (Millipore), blocked with blocking buffer (5% skim milk in TBST) at room temperature, and each membrane was immunoblotted with an anti-phospho-Akt antibody (Cell Signal Technology) at refrigerated temperature. Secondary antibody (anti-rabbit IgG-HRP) was incubated at room temperature for 1 hour, depending on the species of the primary antibody. Membranes were washed three times with TBST at each step. Development was performed using an ECL kit (BioRad) with a Chemidoc device (ATTO), and quantification was performed using a CS4 analyzer program. After development, the membranes were treated with stripping buffer at 60°C for 20 minutes to remove antibodies, and then blocked at room temperature for 1 hour. The membranes were incubated with anti-Akt antibody (Cell Signaling Technology) at room temperature for 1 hour, then with secondary antibody for 1 hour, and developed in the same manner. Quantification was performed based on the signal values calculated by the CS4 analyzer.
[0209] The fusion multispecific protein, including anti-Ang-2 and anti-VEGF antibodies, enhances Akt phosphorylation activity in HUVECs mediated by Ang-1 by inhibiting Ang-2 and VEGF. Figure 19To confirm Ang-1-mediated Akt phosphorylation, the Ang-1-only treatment group was set to achieve 100% Akt phosphorylation. To establish conditions for confirming the inhibitory effects of Ang-2 and VEGF on Ang-1-induced Akt phosphorylation, cells were simultaneously treated with Ang-1, an excess of Ang-2 at 20-fold molar relative to Ang-1, and an excess of VEGF at 0.3-fold molar relative to Ang-1. Under these conditions, Akt phosphorylation decreased to 87% of the Ang-1-only control level. Furthermore, the addition of SEQ ID NO: 63 and SEQ ID NO: 64 fusion proteins at 2-fold molar concentrations relative to Ang-2 restored Ang-2 / VEGF-inhibited Akt phosphorylation to 180% and 156%, respectively. This result confirms that the fusion antibody of the present invention can simultaneously inhibit VEGF and Ang-2, thereby successfully restoring the inhibited Tie2 pathway and exerting a synergistic effect.
[0210] Example 13: Analysis of the growth-inhibiting activity of a multispecific fusion protein including anti-Ang-2 antibody in HUVEC cells The growth-inhibiting activity of a multispecific fusion protein, including an anti-Ang-2 antibody, on HUVEC cells was evaluated.
[0211] Human umbilical vein endothelial cells (HUVEC, Cell Systems) were suspended in assay medium (2% FBS, ECM) and sputtered at 2 × 10⁶ cells per well. 3 Cells were aliquoted into 96-well plates. Recombinant human VEGF-A165 (R&D Systems) was mixed with a multispecific fusion protein including anti-Ang-2 antibody or aflibercept in assay medium to a concentration of 20 ng / mL, and the mixture was incubated at 37°C for 3 hours to induce complex formation. Assay medium containing the complex was added to the 96-well plates containing adherent cells at a 1:1 volume ratio with the existing assay medium in the wells. The 96-well plates treated with assay medium containing the complex were incubated at 37°C for 66 hours. Subsequently, to measure cell growth, CellTiter-Blue (Promega) was added to the 96-well plates and incubated at 37°C for 6 hours. Relative fluorescence units (RFU) were measured at 560 / 590 nm using a SpectraMax M5 (Molecular Devices). The IC50 (half-maximum inhibition) value of the fusion protein was calculated using SoftMax (Molecular Devices) based on the RFU values of the fusion protein concentration.
[0212] As a result, the HUVEC cell growth inhibitory activity of the multispecific fusion proteins comprising anti-Ang-2 antibodies of SEQ ID NO: 54, SEQ ID NO: 60, SEQ ID NO: 63, and SEQ ID NO: 64 of the present invention is shown to be... Figure 20 In the study, the fusion proteins of SEQ ID NO: 54, SEQ ID NO: 60, SEQ ID NO: 63, and SEQ ID NO: 64 according to the present invention were confirmed to have IC50 values of 56 pM, 52 pM, 87 pM, and 57 pM, respectively. This confirms that all multispecific fusion proteins including anti-Ang-2 antibodies have a similar ability to inhibit VEGF-A165-induced HUVEC cell growth.
[0213] Example 14: Inhibitory activity of a multispecific fusion protein including anti-Ang-2 antibody on HUVEC monolayer permeability The effect of a multispecific fusion protein, including an anti-Ang-2 antibody, on vascular permeability was assessed using an in vitro vascular permeability assay (Sigma).
[0214] Human umbilical vein endothelial cells (HUVECs) were cultured on permeable inserts composed of permeable membranes to form a monoendothelial layer, inducing changes in vascular permeability. Vascular permeability was then assessed by measuring the extent to which substances penetrated the HUVEC cell layer of the permeable insert. HUVECs were suspended in endothelial cell growth medium (EGM) containing growth factors. Cells were introduced at a rate of 1 × 10⁶ cells per insert. 5 Cells were seeded into permeability inserts. After 1 day of culture, the medium was replaced with EGM (assay medium) containing 0.5% FBS (fetal bovine serum) and cultured for 24 hours. A multispecific fusion protein including anti-Ang-2 antibody was mixed into the assay medium to achieve a concentration of 10 ng / mL for recombinant human VEGF-A165 (R&D Systems) (a vascular permeability inducing factor), and the medium was replaced with the resulting mixture. Cells were then incubated for 24 hours.
[0215] Human umbilical vein endothelial cells (HUVEC, Cell Systems) were suspended in endothelial cell growth medium (EGM) containing growth factors, and sputtered at a concentration of 1 × 10⁶ cells per well. 5Cells were allocated to permeability inserts and cultured for 1 day. Subsequently, the existing medium was washed with HBSS (Welgene), and EGM (assay medium) containing 0.5% FBS (fetal bovine serum) was added, followed by 24 hours of cell culture. Recombinant human VEGF-A165 (R&D Systems), Ang-2 (R&D Systems) (both vascular permeability inducing factors), and the vascular stabilizing factor Ang-1 (R&D Systems) were added to the assay medium at concentrations of 10 ng / mL, 2000 ng / mL, and 100 ng / mL, respectively. A multispecific fusion protein including anti-Ang-2 antibody was then incorporated, the existing medium was replaced, and the cells were cultured for another 24 hours.
[0216] Subsequently, FITC-glucan (Sigma) was added to the permeability insert to a concentration of 1.5 mg / mL, and monolayer permeability was measured every 1 to 2 hours. Permeability was assessed by collecting a portion of the assay medium from the receiving wells, mixing it with DPBS, transferring the mixture to a 96-well black plate, and measuring relative fluorescence units (RFU) at 485 / 535 nm using a SpectraMax M5 Molecular Devices microplate reader.
[0217] The results of measuring the inhibitory activity of a multispecific fusion protein, including an anti-Ang-2 antibody, on the permeability of HUVEC monolayers are shown in the figure. Figure 21 , Figure 22 and Figure 23 middle.
[0218] First, to evaluate the inhibitory activity against VEGF-A165-induced HUVEC monolayer permeability, the VEGF-only treatment group was set as the positive control (PC), and additionally treated with a multispecific fusion protein including anti-Ang-2 antibody. As a result, such as Figure 21 As can be seen, when HUVECs were treated with the fusion proteins of SEQ ID NO: 54 and SEQ ID NO: 64 according to the present invention at a molar ratio of 1:1 relative to the target protein VEGF-A165, the monolayer permeability increased by VEGF-A165 was inhibited by 84% and 92% respectively compared with the positive control group (PC). Furthermore, as... Figure 22 As can be seen, when the fusion proteins of SEQ ID NO: 63 and SEQ ID NO: 64 according to the present invention are treated at a molar ratio of 1:1 relative to the target protein VEGF-A165, the permeability of the HUVEC monolayer induced by VEGF-A165 is restored by 105% and 81% respectively compared with the positive control group (PC).
[0219] To assess changes in HUVEC monolayer permeability when both VEGF-A165 and Ang-2 are inhibited, the group treated with VEGF, Ang-2, and Ang-1 was designated as the positive control (PC), and treated with a multispecific fusion protein including an anti-Ang-2 antibody. As a result, for the target proteins VEGF-A165 and Ang-2, such as... Figure 23 As can be seen, when the fusion proteins of SEQ ID NO: 54 and SEQ ID NO: 64 according to the present invention are treated with VEGF-A165 at a molar ratio of 1:1, the monolayer permeability increased by VEGF-A165 and Ang-2 is inhibited by 95% and 98% respectively compared with the positive control group (PC).
[0220] The above results confirm the excellent HUVEC monolayer permeability inhibition activity of the fusion protein of this invention.
[0221] Example 15: Evaluation of the vascular leakage inhibition and anti-angiogenic activity of a multispecific fusion protein against Ang-2-fusion in a laser-induced CNV model. In a laser-induced choroidal neovascularization (CNV) mouse model, the vascular leakage inhibition and anti-angiogenic activities of a multispecific fusion protein including an anti-Ang-2 antibody were evaluated. For this purpose, laser photocoagulation was performed on four spots in each eye of 8-week-old male C57BL / 6J mice to induce Bruch's membrane rupture. Immediately after laser irradiation, the test substance was administered once intravitreally to the eye at a dose of 1 μL / eye.
[0222] On day 11 after CNV induction, mice were general anesthetized with ketamine and mydriatic eye drops were administered, followed by intraperitoneal injection of a fluorescent contrast agent. After general anesthesia induction, local anesthesia was induced with anesthetic eye drops, and the mice were placed on an imaging stage for FFA (free fluoroscopic image capture) using an imaging camera (Phoenix). Retinal imaging was performed within 10 minutes of contrast agent administration. The leakage area of each spot was quantitatively analyzed in the acquired images, and ImageJ software (NIH) was used for the same analysis. The solvent group is set to 100%, and the experimental groups are expressed as relative percentages based on this.
[0223] On day 13 after CNV induction, the eyeballs were enucleated and fixed in 4% paraformaldehyde solution for 30 minutes. Subsequently, the choroid was dissected and incubated for 1 hour in a blocking solution containing 5% BSA, 5% normal goat serum, and 0.5% Tx-100, followed by overnight staining with fluorescently labeled isoglucosin GS-IB4 (Invitrogen). After washing with PBS, the choroid was laid flat on a glass slide, and images were acquired using a fluorescence microscope (Olympus). The CNV area of each spot in the acquired images was quantitatively analyzed using ImageJ software (NIH). In the figures, the solvent group was normalized to 100%, and the experimental group is expressed as a percentage relative to the solvent group.
[0224] As a result, the vascular leakage inhibition and anti-angiogenic activities of the multispecific fusion protein, including the anti-Ang-2 antibody, were confirmed in animal models and shown to be... Figure 24 In this study, an anti-Ang-2 antibody (Anti-Ang-2) and an anti-VEGF antibody (Anti-VEGF) were used as controls, along with the protein fused to the Fc C-terminus of SEQ ID NO: 3 according to the invention and aflibercept, respectively. The fusion protein of SEQ ID NO: 63 according to the invention, administered at low doses (19.2 μg / eye, molar equivalent to 15 μg aflibercept) and high doses (25.6 μg / eye, molar equivalent to 20 μg aflibercept), showed dose-dependent results. Furthermore, the high-dose group, administered at the same molar amount as the control group, showed superior efficacy compared to the control group. These results indicate that multispecific fusion proteins including anti-Ang-2 antibodies have a synergistic effect on angiogenesis inhibition and vascular stability by simultaneously inhibiting VEGF and Ang-2. Figure 24 ).
[0225] From this description, those skilled in the art will understand that the present invention can be implemented in other specific forms without altering its technical concept or essential characteristics. Therefore, the above embodiments should be interpreted as exemplary rather than limiting the invention. The scope of the invention should be interpreted to include all modifications or variations derived from the meaning and scope of the following claims and their equivalents (but not from the detailed description above).
Claims
1. A single-domain antibody (sdAb) that specifically binds to angiopoietin-2 (Ang-2) or its antigen-binding fragment, The single-domain antibody includes: (i) CDR1 comprising an amino acid sequence selected from SEQ ID NO: 11, SEQ ID NO: 14, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 23, SEQ ID NO: 26, SEQ ID NO: 29, SEQ ID NO: 32, SEQ ID NO: 35 or SEQ ID NO: 38; (ii) CDR2 comprising an amino acid sequence selected from SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 21, SEQ ID NO: 24, SEQ ID NO: 27, SEQ ID NO: 30, SEQ ID NO: 33, SEQ ID NO: 36 or SEQ ID NO: 39; as well as (iii) CDR3 comprising an amino acid sequence selected from SEQ ID NO: 13, SEQ ID NO: 16, SEQ ID NO: 19, SEQ ID NO: 22, SEQ ID NO: 25, SEQ ID NO: 28, SEQ ID NO: 31, SEQ ID NO: 34, SEQ ID NO: 37 or SEQ ID NO:
40.
2. The single-domain antibody or its antigen-binding fragment according to claim 1, wherein the single-domain antibody comprises: (a) CDR1 of SEQ ID NO: 11, CDR2 of SEQ ID NO: 12 and CDR3 of SEQ ID NO: 13; (b) CDR1 of SEQ ID NO: 14, CDR2 of SEQ ID NO: 15, and CDR3 of SEQ ID NO: 16; (c) CDR1 of SEQ ID NO: 17, CDR2 of SEQ ID NO: 18, and CDR3 of SEQ ID NO: 19; (d) CDR1 of SEQ ID NO: 20, CDR2 of SEQ ID NO: 21, and CDR3 of SEQ ID NO: 22; (e) CDR1 of SEQ ID NO: 23, CDR2 of SEQ ID NO: 24, and CDR3 of SEQ ID NO: 25; (f) CDR1 of SEQ ID NO: 26, CDR2 of SEQ ID NO: 27, and CDR3 of SEQ ID NO: 28; (g) CDR1 of SEQ ID NO: 29, CDR2 of SEQ ID NO: 30, and CDR3 of SEQ ID NO: 31; (h) CDR1 of SEQ ID NO: 32, CDR2 of SEQ ID NO: 33, and CDR3 of SEQ ID NO: 34; (i) CDR1 of SEQ ID NO: 35, CDR2 of SEQ ID NO: 36, and CDR3 of SEQ ID NO: 37; or (j) CDR1 of SEQ ID NO: 38, CDR2 of SEQ ID NO: 39 and CDR3 of SEQ ID NO:
40.
3. The single-domain antibody or its antigen-binding fragment according to claim 1, The single-domain antibody includes a heavy chain variable region, and The heavy chain variable region includes any amino acid sequence selected from SEQ ID NO: 1 to SEQ ID NO: 10, or any amino acid sequence having at least 90% sequence identity with an amino acid sequence selected from SEQ ID NO: 1 to SEQ ID NO:
10.
4. The single-domain antibody or its antigen-binding fragment according to claim 1, wherein the single-domain antibody does not bind to angiopoietin-1 (Ang-1) or exhibits low reactivity to Ang-1.
5. The single-domain antibody or its antigen-binding fragment according to claim 1, wherein the single-domain antibody inhibits the binding of angiopoietin-2 to the TEK / Tie2 receptor, thereby activating the TEK / Tie2 signaling pathway.
6. The single-domain antibody or its antigen-binding fragment according to claim 1, wherein the single-domain antibody is in the form of fusion with a biocompatible material.
7. The single-domain antibody or its antigen-binding fragment according to claim 6, wherein the biocompatible material is selected from polyethylene glycol (PEG), cholesterol, albumin and its fragments, albumin-binding substances, polymers of specific amino acid sequence repeating units, FcRn-binding substances, in vivo connective tissue or its derivatives, nucleotides, fibronectin, transferrin, carbohydrates, polymers, and combinations thereof.
8. A multispecific fusion protein, comprising: The single-domain antibody (sdAb) that specifically binds to angiopoietin-2 (Ang-2) according to claim 1, or its antigen-binding fragment; and the second antigen-binding portion.
9. The multispecific fusion protein of claim 8, wherein the single-domain antibody (sdAb) or its antigen-binding fragment that specifically binds to angiopoietin-2 (Ang-2) is directly linked to the second antigen-binding portion via a peptide bond, or indirectly linked to the second antigen-binding portion via a linker.
10. The multispecific fusion protein according to claim 8, wherein the second antigen-binding portion is an anti-VEGF antibody that specifically binds to VEGF or its antigen-binding fragment.
11. The multispecific fusion protein according to claim 10, wherein the anti-VEGF antibody is aflibercept, bevacizumab, broxolizumab, or ranibizumab.
12. The multispecific fusion protein of claim 10, wherein the fusion protein comprises any amino acid sequence selected from SEQ ID NO: 48 to SEQ ID NO: 65, or an amino acid sequence having at least 90% sequence identity with any amino acid sequence selected from SEQ ID NO: 48 to SEQ ID NO:
65.
13. A bispecific antibody that simultaneously binds Ang-2 and VEGF, comprising: The single-domain antibody (sdAb) or its antigen-binding fragment that specifically binds to angiopoietin-2 (Ang-2) according to claim 1; And anti-VEGF antibodies or their antigen-binding fragments that specifically bind to VEGF.
14. A polynucleotide encoding a single-domain antibody or antigen-binding fragment thereof according to any one of claims 1 to 7, a fusion protein according to any one of claims 8 to 12, or a bispecific antibody according to claim 13.
15. An expression vector comprising the polynucleotide according to claim 14.
16. A host cell comprising the expression vector according to claim 14.
17. A method for producing antibodies, comprising culturing cells according to claim 16.
18. A pharmaceutical composition for the prevention or treatment of diseases associated with angiopoietin-2 activation or overexpression, comprising, as an active ingredient, a single-domain antibody or antigen-binding fragment thereof that specifically binds to angiopoietin-2 (Ang-2) according to any one of claims 1 to 7.
19. The pharmaceutical composition of claim 18, wherein the disease associated with angiopoietin-2 activation or overexpression is a vascular disease.
20. The pharmaceutical composition of claim 19, wherein the vascular disease is selected from age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR), retinal vein occlusion (RVO), retinopathy of prematurity (ROP), neovascular glaucoma, proliferative diabetic retinopathy (pDR), vascular adhesion, idiopathic systemic capillary leak syndrome (Clarkson's disease / ISCLS), osteoarthritis, rheumatoid arthritis, psoriasis, Crohn's disease, ulcers, diabetic nephropathy, nephritis, cirrhosis, neurodegenerative diseases, and atherosclerosis.
21. A method for preventing or treating a disease associated with angiopoietin-2 activation or overexpression, comprising administering the pharmaceutical composition of claim 18 to a subject.
Citation Information
Patent Citations
Composition for preventing and treating vascular disorders
KR101913940B1
